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ABSTRACT  
 
Radiotherapy is central to the management of a number of human cancers, either as an 
adjuvant or primary treatment modality.  The principal objective in irradiating tumors is to permanently 
inhibit their proliferative ability.  More than half of all malignancies are primarily treated with radiation, 
but the heterotypic nature of tumor cells greatly complicates their response to radiotherapy.  The need 
for reliable parameters to predict tumor and normal tissue response to radiation is therefore a prime 
concern of clinical oncology.   
Post-operative radiotherapy has commonly been used for early stage breast cancer to treat 
residual disease.  There is continued debate as to what might be the proper dose per fraction as well as 
the total dose of radiation that needs to be prescribed to prevent disease recurrence.  Countries outside 
the US have adopted increased dose fractionation (i.e., hypofractionation) schemes for early stage 
breast cancer as a standard of practice; however there is a lack of confidence in these approaches in the 
United States.    
The tumor microenvironment plays a significant role in regulating the progression of 
carcinomas, although the mechanisms are not entirely clear.  The primary objective of this work was to 
characterize, through mechanobiological and radiobiological modeling, a test bed for radiotherapy 
fractionation techniques assessment.  Our goal is to understand how the tumor microenvironment 
responds to dose fractionation schemes for Breast Conserving Therapy (BCT).  Although carcinomas are 
the major concern for oncology, in this project, the goal is to understand how the stromal 
microenvironment influences behavior of the cancer cell populations. By classifying 3-D cellular co-
cultures as having a reactive or quiescent stroma using the mechanobiology profile (culture stiffness, 
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cellular activation, differentiation, and proliferation) we aim to differentiate the effectiveness of various 
fractionation schemes. 
The benefits of understanding heterotypic signaling in post-surgical breast cancer recurrence 
would be to assist radiation oncologists in designing an improved therapeutic strategy.  To relate the 
parameters of cellular function to therapeutic prescriptions which offer an enhanced clinical outcome 
would address the lack of knowledge regarding recurrence of disease, tumor control and whether the 
tumor microenvironment requires more aggressive treatments. 
In our work to date, we have developed a three-dimensional co-culture model to determine 
how alternative dose fractionations affect the post-surgical microenvironment.  This work suggests that 
3-D co-cultures provide the microenvironmental cues needed to reexamine the radiobiological basis 
underlying radiation therapy.   
The findings suggest dose escalation to the tumor region may deactivate the reactive stroma, 
thus minimizing the cancer promoting environment.  Large-fraction irradiation may be used to sterilize 
residual tumor cells and inhibit activation of intracellular transduction pathways that are promoted 
during the post-surgical wound-healing period.  Wound-healing mechanisms are characterized by 
angiogenesis, fibroplasia, collagen production and granulation tissue formation all of which impact 
patient prognosis.  In fact, tumor dose escalation trials have been proven to reduce local recurrence 
rates and thus new approaches to partial breast irradiation and tumor bed boosting using external-beam 
electrons and intensity-modulated radiotherapy (IMRT) techniques are currently under use.  These 
techniques minimize absorbed dose to healthy breast tissues.  Treating the residual cancer cells and the 
reactive stroma that has been stimulated by wound healing requires that we look at the interplay 
between cell types as well as the mechanical and biochemical factors driving disease.   
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We have discovered that the reason hypofractionation schemes (larger irradiation fractions per 
day with less total dose) offer therapeutic advantages to some patients could be that it is more effective 
at treating the reactive stroma.  We can kill the cancer cells at the standard rate (180 cGy/fraction), but 
we have found the larger fractions specifically inhibit wound healing mechanisms by inactivating stromal 
fibroblasts.  The long term goal would be to reduce recurrence rates for early stage breast cancer by 
treating postsurgical regions most likely to harbor residual tumor cells.  Ionizing radiation stress and its 
effect on ECM mediated cellular functions continues to be an evolving area of research.  This study is an 
initial step in my career plans to study stromal modulation of epithelial tumors. It is also my career goal 
to integrate basic science experiments and engineering tools into clinical practice. 
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CHAPTER 1 
INTRODUCTION 
 
1.1 Challenges in Fractionated Radiotherapy for Breast Cancer 
Breast conserving surgery (BCS) or lumpectomy for early stage breast cancer has revolutionized 
patient care over the last two decades.  Early stage breast cancers with small primary lesions have been 
diagnosed through increased use of diagnostic mammography; thus making BCS the new gold standard 
over mastectomy (Veronesi et al. 2002; Goh & Yong 2004).  An improved cosmetic outcome and overall 
quality of life stemming from the less invasive surgery is a significant benefit at the expense of a 
potential increased risk in local recurrence (Fisher et al. 2002).  Clinical observations coupled with the 
notion that surgery modifies the growth kinetics of breast cancer micrometastasis (Demicheli et al. 
2001; Baum et al. 2005), support the hypothesis that surgery itself presents a perturbing factor for 
metastasis development in humans.  The effect of wound healing on tumor growth has been shown in 
studies of mice (Baker et al. 1989), which assessed the number of cells from three different tumor 
models needed to induce tumors at 50% of the injected sites (TD/50) when introduced into surgically 
wounded tissue compared with non-wounded tissue.  The studies found there was a greater likelihood 
of recurrence in wounded tissues compared to non-wounded tissues.  The difference was interpreted as 
the result of the presence of growth factors derived from the traumatized tissue and the inflammatory 
cells at the wound site.  Also, studies by (Kaplan et al. 2005) and (Tsuchiya et al. 2003) found that tumor 
derived growth factors were able to create the formation of specific cellular cluster sites or 
premetastatic niches where tumor cells could successfully metastasize and develop into viable tumors.  
 2 
 
The premetastatic niche could be thought of as a base for cancer cells to adhere and proliferate, or a 
budding version of the reactive stroma.    
The complex cellular behavior in forming these pre-metastatic niches is paralleled in some 
respects to the events that occur during normal wound healing.  The healing process conveys motility to 
the surrounding cells on the periphery of the cavity to become invasive and move towards the core of 
the wound to heal the breast after surgical removal of the tumor.  During this phase any residual 
neoplastic cells at the excision site are also exposed to the physiological signaling associated with 
inflammation and wound repair.  This effect has previously been related to growth factors produced by 
stromal cells during the wound healing process (Belletti et al. 2008).  This indicates that growth factors 
in the microenvironment stimulate mammary cells, leading to residual disease locally following BCS.   
Ultimately this contributes to recurrences of breast cancer.   
Possible explanations of residual disease include: (1) incomplete removal of the tumor, possibly 
due to breast duct anatomy and extensive intraductal components (Mannino & Yarnold 2009); (2) 
stimulation of migration and growth of residual occult tumor cells in response to the surgical wound 
healing (Tagliabue et al. 2003; Hockel & Dornhofer 2005; Belletti et al. 2008).  However, the combined 
modalities of chemo and radiotherapy (RT) with BCS have proven in many trials to give similar local 
recurrence rates as that of mastectomy alone (Fisher et al. 2002; Veronesi et al. 2002).  The ability of 
radiation to eradicate the microscopic foci of malignant cells remaining after a breast tumor mass is 
surgically removed, ultimately led to breast-conserving therapy (BCT) as an option for many breast 
cancer patients.   This study focuses primarily on radiotherapy.  Current clinical trials suggest radiation 
dose escalation to the tumor bed region may decrease the probability of recurrences at the surgical scar 
site and eradication of residual disease, if it’s tolerated by patients.  Ultimately, dose escalation is 
limited by the volume of breast irradiated or the amount of absorbed dose received by adjacent critical 
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normal tissues (ribs, lung, heart, etc.).  Larger irradiation fractions may be used to sterilize residual 
tumor, reactive stroma and inhibit activation of intracellular transduction pathways that initiate wound-
healing mechanisms characterized by angiogenesis, fibroplasia, collagen production and granulation 
tissue formation. Important to the treatment of any disease is a simple relationship between treatment 
and effect.  In fact, the Standardization of Breast Radiotherapy Trails (START), have looked at late 
adverse effects and tumor control, which strengthen evidence in favor of alternative fractionation 
schemes, e.g., hypofractionated regimens, with potential for fewer adverse effects to normal breast 
tissues (Abram et al. 2008).  Hypofractionation is a radiation therapy schedule that delivers a larger dose 
per fraction but a lower total dose than the conventional 25 fractions of 180 cGy (centigray) each for a 
total dose of 4500 cGy.   
Improvements in treatment planning and radiation delivery techniques have allowed for the 
inclusion of radiobiological aspects, such as cell sensitivity, activation, proliferation or cell viability to 
enhance treatment optimization (Fowler 2001; Muriel 2002; Yang & Xing 2005) parameters which we 
have explored in our studies.  We initially looked at the isolated stromal component response to IR.  We 
then developed a residual disease model to represent the incomplete removal of the tumor or the 
stimulation of residual occult tumor cells in response to the surgical wound healing and then under IR.   
1.2 Breast Conserving Therapy (BCT) 
Breast-conserving surgery followed by external radiotherapy is the current standard of 
treatment for localized cancer of the breast (Belletti et al. 2008).  The common understanding is that RT 
sterilizes the tumor bed of residual tumor cells. However, the absolute effect of radiotherapy on the 
microenviroment of the post-surgical region is still unclear.  There is a need to study the factors that play 
a vital role in the elimination of tumor cells and suppression of reactive stroma following surgical 
procedures.  
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Although the primary objective of ionizing radiation (IR) exposure is to control growth of 
cancerous epithelial cells (cancer cells), IR-induced gene expression in cells of adjacent stroma also 
modulates conditions that affect tumor growth (Barcellos-Hoff 2008, 2010).  Stroma includes fibroblast, 
macrophage, lymphocyte, and endothelial cells; however, the focus of this study is the influence of 
cancerous epithelial and fibroblasts interaction on the mechanical environment that modulates the 
activity of signaling networks directing cell functions, including those of cancer cells. 
We hypothesized that radiotherapy may not only decrease breast cancer cell survival but 
influence tumor microenvironment by changing the cell phenotype leading to tissue stiffness and cell 
signaling that promotes tumorigenesis and metastasis (Vaidya et al. 2004; Barcellos-Hoff et al. 2005), all 
of which alter patient prognosis.  RT also impacts the post-surgical healing process. Wound healing 
processes are mechanically regulated (Grinnell 1994; Hinz et al. 2001; Tomasek et al. 2002; Wipff & Hinz 
2009).  Wound repair is known to eliminate injured cells and tissue; there is great deal of interest in 
examining it as a possible factor affecting the incidence of residual carcinoma following an incomplete 
excision of the tumor.  Wound healing involves multiple stages including hemostasis, inflammation, 
tissue regeneration and matrix remodeling (Hockel & Dornhofer 2005).  Under matrix remodeling, the 
extracellular matrix (ECM) stiffness and tissue strength increases from collagen upregulation and cross-
linking to form scar tissue (Thibeault et al. 2002).  The fibroblasts exert force to close the wound 
(Amadeu et al. 2003).  It has long been recognized that wound healing is an important element during 
treatment and we would like to use our model to focus on the stromal components and their interaction 
to growth factors and IR.  Investigators have noted that a stimulatory effect of wound healing on post-
surgical residual disease contributes to the poor prognostic value of standard radiotherapy fractionation 
schemes.  We investigated the altered fractionation schemes to evaluate the microenvironments 
response under RT.     
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1.3 Need for physical modeling in cancer treatment  
Treatment regimens are conventionally designed through a range of controlled clinical trials.  
Clinical trials are vital prerequisites to establishing therapeutic principles.  However, trials are lengthy 
processes which involve optimization of many coupled parameters for their success.  In-vitro models 
simulate a less complex environment to isolate a specific set of tissue components for study.  They allow 
us to overcome some of the limitations encountered by clinical trials.  Beside animal models and single 
cell experiments, which are often used for pre-clinical studies, we propose models encompassing 
physical and engineering concepts that represent the systems biology approach.   
Physical models used in cancer research provide simplified tools that reproduce isolated aspects 
of the tissue system.  They do not reflect accurately the fine details of the real system.  To compensate 
for some of its deficiencies, we propose a co-culture model which blends the cancer cell model and 
wound healing, as opposed to one cell type model.  This process holds significant promise for providing 
new understanding of RT fractionation protocols on residual disease.  Thus, we wish to model and 
examine the effects of irradiation delivered to cell cultures that represent a subset of the conditions of 
adjuvant patient treatments following BCS.   
There is a large amount of cross-talk between tumor cells and surrounding stromal cells, which 
aids in post-surgical wound healing and metastatic invasion from residual disease.  The tumor-cell 
microenvironment is recognized as an important determinant in the development and invasive potential 
of breast cancer (Bissell et al. 2002; Allinen et al. 2004).  Cells are very sensitive to chemical and 
mechanical changes in their microenvironment, which can provide cues for developmental and other 
intracellular programs (Paszek et al. 2005; Engler et al. 2006).  Culturing epithelial cells in 3D matrices 
leads to a difference in receptor expression, localization, and sensitivity to treatments when compared 
with a 2D culture. 2D cell cultures have considerable difference in morphology, cell-cell, and cell-matrix 
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interactions, and differentiation when compared to the more physiological 3D environments (Cukierman 
et al. 2001; Yamada & Cukierman 2007).  Similarly, tumor cells interact with the microenvironment, 
which is known to be a key regulatory step for cancer progression. Innovative work in this field has 
shown that cancerous phenotypes can be stimulated (Olumi et al. 1999; Park et al. 2000) or suppressed 
(Weaver et al. 1997) simply by altering the tumor microenvironment. The tumor microenvironment, or 
stroma, in ductal carcinoma consists of ECM proteins, such as collagen and a variety of cells including 
fibroblasts and macrophages. Reactive stroma, characterized by the presence of cancer-activated 
fibroblasts (CAFs) that express α-smooth muscle (α-SMA) protein which cause ECM stiffness (Qayyum & 
Insana 2012b) is associated with poor prognosis in breast cancer (Bergamaschi et al. 2008). 
Fibroblasts have been widely studied in 3D, most frequently in a collagen matrix, which is more 
representative of their natural environment (Grinnell 2003). Collagen was chosen because it resembles 
the ECM milieu of invasive breast carcinoma better than Matrigel, which may not simulate the ECM of 
normal breast tissues (Su et al. 2007).  Many studies have shown that fibroblasts play a major role in the 
initiation and progression of carcinoma cells (Desmouliere et al. 2004; Orimo et al. 2005; Kalluri & 
Zeisberg 2006).  Although current 3D models of breast cancer are a considerable improvement on 2D 
systems, they are limited in their focus on the behavior of cancer cells only. The complex nature of the 
stromal component in the breast means that the study of these cell types alone is unlikely to 
recapitulate what is seen in the in-vivo environment after BCS.  A convenient way to study the complex 
mechanisms underlying epithelial–mesenchymal interactions in-vitro is through the reconstitution of 
cellular behavior in a 3D environment obtained by growing epithelial cells and stromal fibroblasts within 
collagen matrices.  3D cultures are composed of proliferating cells, non-proliferating viable cells, and 
activated cells resembling the multiple phenotypes found in the post-surgical microenvironment.  Thus 
we propose a progressive culture model approach for investigating stromal-epithelial interactions in the 
microenvironment of the residual disease after BCS under RT.   
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Understanding how cell and molecular responses to IR produce organism reactions may be 
difficult in a reductionist model that emphasizes components and pathways, rather than on network 
interconnectivity and tissue context.  Cells receive information about how they should behave from their 
microenvironment, which normally consists of other cells, insoluble ECM proteins, soluble hormones 
and cytokines. Thus, the cell-centric view in radiobiology has begun to shift toward achieving a broad 
understanding of cell systems. This view is paralleled in current cancer research with a new appreciation 
for the complicity of normal cells in processes involved during the formation of tumors (Barcellos-Hoff & 
Costes 2006).   
1.4 Specific Aims and Research Conducted  
The findings of Herskind & Rodemann (2000) show IR prompts the release of transforming 
growth factor beta 1 (TGF-β1) that directs the differentiation of fibroblast cells to further increase 
growth factor expression in a positive feedback manner.  This process stiffens the peri-epithelial ECM 
that encourages cancer cell growth through integrin signaling (Levental et al. 2009; Shieh 2011).   While 
the balance of pro- and anti-tumorigenic IR responses favors the latter, the margin between cancer and 
noncancer cell effects are small at patient doses that can be tolerated.  Consequently, optimal IR 
fractionation in adjuvant applications involves a careful balance among competing factors.  
Given the complex multifactorial nature of tissue responses to various treatment strategies, it is 
essential to explore the therapeutic responses of the fibroblasts cells that interact with cancerous 
epithelia.  We begin this process by investigating the effects of photon RT from the perspective of 
isolated stromal-cell radiobiology.  While others have looked at the stromal environment from a cell 
centric view, we have looked at cell function in the context of the mechanical properties of the stromal 
microenvironment.  Breast tumor growth depends on the cellular microenvironment and tissue 
mechanical properties.  By studying the stromal environment, we can explore their interactions with IR 
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to modify the mechano-environment influencing the cancer cell-to-noncancer cell therapeutic ratio 
during fractionated RT. 
The general accomplishments of this dissertation are: 
 Parametric description of isolated 3D stromal cell culture responses to fractionated 
radiotherapy.  The effects of fractionation schemes on collagen matrix stiffness and fibroblast 
activation were studied using this culture model. 
 Establishing a 3-D cell co-culture model. Incorporating more breast tissue components such as 
cancerous mammary cell lines into fibroblast-collagen gel to mimic more natural signaling 
conditions.  The goal was to produce co-cultures that will be used to deliver fractionated courses 
of radiation prescriptions that enable measurements of the cellular microenvironment. 
 Exposing the co-culture models to altered fractionation schemes to process optimized dose 
per fraction for eradication of residual disease.  We tracked a feature space that includes 
collagen matrix stiffness, fibroblast activation and epithelial cell proliferation. 
Table 1 provides a glossary of each experiment and its corresponding section within this paper. 
Table 1 Model evolution of the experiment conducted for this thesis. 
 With/with Out Radiation Section in Paper 
Collagen only Base material 3.3.2 
Collagen + MRC 5 Fibroblast Stroma Cell Culture 3.3.3 
Collagen + MRC-5 Fibroblast +/- 
TGF-β1 
Reactive Stroma Cell Culture 3.3.4 
Collagen + Fibroblast + MCF-7 
cancer cells 
Co-culture 4.2 
Collagen + Fibroblast + MCF-7 
cancer cells +/- TGF-β1 
Residual disease in wound 
healing environment 
4.3 
 
By using the co-culture model for residual breast cancer following lumpectomy, we can begin to 
interrogate the link between cancer and wound healing. Cancer is referred to as a wound that does not 
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heal; the reactive stroma does not dissipate as it does following wound healing.  The cell-culture model 
serves as a tool to evaluate fractionation schemes based on a new understanding of the radiobiology of 
the response of cells in culture to IR.  We tracked cell proliferation, differentiation, and ECM stiffening 
in 3-D collagen co-cultures that were stimulated by growth-factor and irradiation.  This is an 
important step in acquiring a systems-radiobiology perspective for optimizing breast cancer RT. 
Our initial study found IR fraction size affects the matrix stiffness and fibroblast activation of a 
reactive stroma differently.  If it is more important to reduce fibroblast activation than matrix stiffness, 
then larger fractions are recommended.  However large radiation dose fractions will quickly cross link 
the collagen to stiffen the matrix.  If stiffening is the dominant factor in the reactive stroma promoting 
cancer cell progression, then smaller fractions are recommended.   Therefore, our observations would 
imply that staging the reactive stroma, might be an important step in assertively selecting fractionation 
dose schemes.  Irradiation of the co-culture model was expected to target the microscopic spread of 
disease and inhibit signaling from the wound healing response, thus reducing the probability of 
recurrence.  We would predict that treating the excised tumor area with an optimum dose of radiation 
not only kills residual cancer cells within the vicinity, but also inhibits the wound healing by inactivating 
stromal fibroblasts.  The long term goal would be to reduce the recurrence rates for early stage breast 
cancer by treating regions most likely to harbor residual tumor cells.    
1.5 Outline of this Dissertation      
Optimum fractionation in radiotherapy occurs when tumor control is improved without 
enhancing adverse reactions in the surrounding tissue.  It depends on the proliferative state of the 
tumor cells relative to that of the normal tissue at risk.  This is where biological understanding and 
clinical radiation oncology meet.  The initial study was undertaken on stromal component responses to 
altered fractionation schemes.  In order to build a more relevant in-vitro model, we incorporated more 
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components to represent a subset of the conditions of adjuvant patient treatments following BCS.  
Chapter 2 is a study on the research design of building the physical model of the cancer 
microenvironment after BCS as well as discussing radiobiological fractionation protocols in the clinic.  
The response of stromal components to fractionated radiotherapy is explored in Chapter 3, which is 
modified from a paper published in the International Journal of Radiation Biology (Qayyum & Insana 
2012a).  As an extension of Chapter 3, Chapter 4 examines stromal-epithelial cell interactions following 
fractionated radiotherapy.  Finally, Chapter 5 describes the general conclusions about the developments 
presented in previous chapters, and provides an outline of possible future directions derived from this 
dissertation work.   
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CHAPTER 2 
MODELING IN RADIOTHERAPY 
 
2.1 Physical modeling in radiotherapy cancer treatment  
The biological requirements integral to the survival of a cancer cell are likely very different when 
it is embedded within a mature tumor microenvironment, which is composed of stromal fibroblasts, 
myofibroblasts, and mature matrix – than it is during the initial stages of tumor formation or near the 
tumor margins.  Cancer cells within a mature tumor microenvironment are more likely to be resistant to 
adjuvant therapies for multiple reasons. One reason is cancer therapies are not likely to reach cancer 
cells within dense primary tumor stroma as easily as they would if those cells were within emerging 
tumor microenvironments.  The inadequate response of primary solid tumors to chemotherapy is the 
poor penetration and distribution of such agents in the tumor tissue due to interstitial hypertension, 
which is a universal characteristic of solid tumors (Camara et al. 2007).   Within the tumor cell 
microenvironment, RT effectiveness is closely dependent on oxygen availability at the time of 
treatment.  Hypoxic cells are 2 to 3 times less radiosensitive than well-oxygenated cells.  The hypoxic cell 
fraction in solid tumors ranges from less than 1% to more than 50%.  Hypoxia in the tumor 
microenvironment may be a result of increased interstitial pressure, which leads to vascular collapse 
with resulting areas of transient or persistent hypo- perfusion, local hypoxia, and acidosis (Wachsberger 
et al. 2003).  Many patients with cancer are anemic; a factor that may also contribute to localized 
hypoxia and that has an adverse effect on curability of a tumor by RT (Gunderson & Tepper 2007).   
Therefore, studying alternative fractionation (e.g. hypofractionation) schemes may improve the ability 
to eradicate resistant residual cancer cells and reactive stroma.   
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Breast cancer is a complex and heterogeneous disease.  In the laboratory, breast cancer is often 
modeled using established cell lines.  A variety of models for in-vitro cancer growth and treatment have 
made significant advances toward mimicking in-vivo tumor architecture and growth behavior as 
compared to cells grown on 2D tissue culture substrates.  We developed an in-vitro system using 
immortalized and widely available cell lines that would serve as a model for the study of the paracrine 
interactions in breast cancer post-surgery. 
The ECM is a heterogeneous composition of proteoglycans, proteins, and signaling molecules 
that was originally known for its role in providing structural support to cells and as a milieu for cell 
migration.  The ECM influences cell differentiation, proliferation, survival, and migration through both 
biochemical interactions (cell adhesion and presentation of growth factors) and mechanical cues 
(stiffness and deformability).  For example, expression levels of the ECM protein lysyl oxidase (LOX), 
which is responsible for collagen cross-linking, is elevated in cancer patients and associated with 
metastasis and reduced patient survival (Erler et al., 2006).  In figure 1 is a cartoon depicting the stages 
of breast tumorigenesis (A) from left to right; normal ducts, ductal carcinoma in situ and invasive 
phenotype, highlighting key changes within the tissue stroma. (B) Force-dependent focal adhesion 
maturation mediated by elevated tumor matrix stiffness. Integrins are bidirectional mechanosensors 
that integrate biochemical and biophysical cues from the matrix and the actin cytoskeleton and 
transduce cell-generated force to the surrounding microenvironment. Activated integrins bind to ECM 
proteins via cooperative interactions between their alpha and beta extracellular domains and form 
nascent highly dynamic adhesion signaling complexes. In response to external mechanical force or 
elevated cell-generated contractility integrin clustering is enhanced and the recruitment of multiple 
integrin adhesion plaque proteins including talin and vinculin is favored. These, in turn, associate with 
the actin cytoskeleton and multiple signaling proteins including focal adhesion kinase (FAK), Src family 
kinases, and integrin-linked kinase, to promote cell growth, survival, migration and differentiation (Yu et 
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al. 2011).  Matrix stiffening, which reflects elevated matrix deposition, linearization and cross-linking, 
can co-operate with oncogenic signaling to enhance cell-generated contractility to foster integrin 
associations and focal adhesion maturation. Maturation of focal adhesions promotes cell generated 
forces by enhancing Rho GTPase and ERK-mediated acto-myosin contractility—which feed forward to 
further promote integrin clustering and focal adhesion assembly and transmit acto-myosin-generated 
cellular forces to the ECM (Dobaczewski et al. 2010) 
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Figure 1 Malignant transformation of mammary epithelial cells is regulated by matrix stiffness. Breast transformation ensues 
through progressive of genetic alterations in the epithelial cells residing within the mammary ducts. The tissue stroma 
responds to these epithelial alterations by initiating a desmoplastic response that is characterized by activation and 
differentiation of fibroblasts, infiltration of immune cells, increased secretion of growth factors and cytokines, and elevated 
matrix synthesis and remodeling that manifests as matrix stiffening. (a) Cartoon depicting the stages of breast tumorigenesis 
(from left to right;normal ducts, ductal carcinoma in situ and invasive phenotype), highlighting key changes within the tissue 
stroma. (b) Force dependent focal adhesion maturation mediated by elevated tumor matrix stiffness. Integrins are 
bidirectional mechanosensors that integrate biochemical and biophysical cues from the matrix and the actin cytoskeleton 
and transduce cell-generated force to the surrounding microenvironment. Activated integrins bind to ECM proteins via 
cooperative interactions between their alpha and beta extracellular domains and form nascent highly dynamic adhesion 
signaling complexes. In response to external mechanical force or elevated cell-generated contractility integrin clustering is 
enhanced and the recruitment of multiple integrin adhesion plaque proteins including talin and vinculin is favored. These, in 
turn, associate with the actin cytoskeleton and multiple signaling proteins including focal adhesion kinase (FAK), Src family 
kinases, and integrin-linked kinase, to promote cell growth, survival, migration and differentiation. Matrix stiffening, which 
reflects elevated matrix deposition, linearization and cross-linking, can co-operate with oncogenic signaling to enhance cell-
generated contractility to foster integrin associations and focal adhesion maturation. Maturation of focal adhesions 
promotes cell generated forces by enhancing Rho GTPase and ERK-mediated acto-myosin contractility–which feed forward 
to further promote integrin clustering and focal adhesion assembly and transmit acto-myosin-generated cellular forces to 
the ECM. (Reprinted from Mammary epithelial cell: Influence of extracellular matrix composition and organization during 
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development and tumorigenesis, 39 /11, Laura Kass,Janine T. Erler,Micah Dembo,Valerie M. Weaver,2007, with appropriate 
permission from Elsevier as published in (Kass et al. 2007)). 
In a wound response, platelets not only release the clotting factors needed to control the 
bleeding and loss of fluid and electrolytes but they also provide a cascade of chemical signals, known as 
cytokines or growth factors, that initiate the healing response (Guo & Dipietro 2010). The two most 
important signals are platelet-derived growth factor (PDGF) and TGF-β1. TGF-β1 adds an important 
signal for the initiation of the healing cascade by attracting macrophages and stimulates them to secrete 
additional cytokines including FGF (fibroblast growth factor), PDGF, TNFa (tumor necrosis alpha) and IL-1 
(interleukin-1). In addition, TGF-β1 further enhances fibroblast and smooth muscle cell chemotaxis and 
modulates collagen and collagenase expression (Diegelmann & Evans 2004).  TGF-β1 regulates ECM 
tension and stiffness through increasing the expression of ECM proteins by tumor cells or CAFs and 
thereby increase the oncogenic activities (e.g. proliferation) of cancer cells (Ungefroren et al. 2011).  
TGF-β1 in the cancer model is produced by cancerous epithelia and CAFs. Cancer cells in advanced 
tumors are unresponsive to the growth inhibitory effects of TGF-β1, but instead increase cancer cell 
growth, survival, motility and invasion (Bagely 2010).  Paracrine interactions between tumor cells and 
fibroblasts then become important determinants of cell proliferation, angiogenesis, and metastasis 
(Ronnov-Jessen et al. 1996). 
We introduced a 3D co-culture model using cancer cells and normal fibroblasts in a collagen 
matrix. 3D cell cultures of standard cell lines provide biologically representative samples of cell-ECM 
systems for mechanobiology studies that can be assayed with standard phase contrast and confocal 
fluorescence microscopy. These samples are homogeneous with a controlled geometry that allows for 
accurate mechanical measurements.  3D cell cultures lack perfusion and tissue organization, but they 
model the mechanical dynamics of ECM and interstitial fluids moving through a cell-matrix system that 
are the primary components of elasticity. 
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The fibroblast-to-myofibroblast cellular transformation is well maintained in the tumor stroma 
of many cancers, as well as during wound healing, but the process is poorly understood (Carlson & 
Longaker 2004) and can only be characterized by the cellular marker α-SMA (Wang et al. 2005).  The 
fibroblast-populated collagen matrix has been utilized as an in-vitro model of wound healing for more 
than 2 decades (Carlson & Longaker 2004).  Studies of both tumor development and the process of 
wound healing have suggested a critical role for ECM components that are produced by fibroblasts.  The 
development of fibrosis appears to mimic the same cellular processes as wound healing, a major 
difference being the sustained overproduction of ECM components in fibrosis (Grinnell 2003; Holliday et 
al. 2009). 
Carcinoma-associated fibroblasts (CAFs) also known as myofibroblasts are normally induced 
transiently during wound healing, but inappropriate induction of myofibroblasts causes organ fibrosis, 
which greatly enhances the risk of subsequent cancer development.  As our previous studies showed, 
myofibroblasts are found in the reactive tumor stroma, the processes involved in their development and 
activation are central to our investigation. 
MRC-5 human lung fibroblasts have been used extensively with both epithelial lines and 
respond predictably to biochemical and mechanical stimuli.  These cell lines represent polyclonal 
populations of cells that have adapted to tissue culture conditions but retain many of their phenotypic 
and genotypic properties over many passages.(Lacroix & Leclercq 2004; Stuelten et al. 2005; Fillmore & 
Kuperwasser 2008)  This suggests that, despite their acquired ability to grow in vitro, cell lines continue 
to share many of the molecular and genetic features of the primary breast cancers from which they 
were derived.  With the role of the stroma regulating breast cancer behavior receiving more attention, 
many investigators are incorporating stromal cells, such as fibroblasts, into these cultures.   
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To generate a tumor-like mechanobiological environment, the matrix is seeded with malignantly 
transformed epithelial cells (Michigan Cancer Foudation, MCF-7) cells.  This cell line was chosen because 
these cells over express integrins and create focal adhesions points leading to contraction.  MCF-7 cells 
are  well-respected as a model for in-vitro study of neoplastic mammary cells (Rossi et al. 2000).  
Integrin’s, which are trans-membrane adhesive receptors, are responsible for perceiving and responding 
to changes in both the extracellular microenvironment and the inner cell by linking the ECM to the 
cytoskeleton.  For example, beta-1 integrins, among others, have been associated in the regulation of 
protein Kinase B (PKB) also known as Akt, which plays a crucial role in regulating breast cancer cell 
invasion. Furthermore, inhibition of beta-1 integrin has been shown to result in a change of invasive 
strategy (Castelló-Cros et al. 2009). 
In our model the fibroblasts were co-cultured with tumorigenic breast epithelial cells, MCF-7, 
and stimulated with TGFβ1, a growth factor known to induce the fibroblast-to-myofibroblast phenotypic 
change.  Others have investigated 3-D cell co-cultures to study irradiated mammary cell lines (Rossi et al. 
2000).  Those studies have guided our proposed approach (MRC-5 fibroblasts with MCF-7 epithelial).  
Our initial work in this study has resulted in finding co-culture with MCF-7 cells induced transformation 
in fibroblasts-to-myofibroblast.  Cancerous epithelial cell secrete TGF-β1 to cause differentiation of the 
fibroblast-to-myofibroblast.  This would be true for a tumor forming model, but since our model has 
been designed to represent the wound healing process after lumpectomy of early stage breast cancer, 
we incorporated a sparse distribution of MCF-7 cells and denser amounts of fibroblast cells.  We then 
stimulated the fibroblast exogenously with TGF-β1 to mimic the wound environment.  Literature 
indicates that the doubling time for sparse cancer cells is about 2 weeks (Rossi et al. 2000; Shen et al. 
2006).  Patients are treated anywhere from 2- 4 weeks post-surgery at the discretion of the physician.  
Our model was built to mimic the residual disease at this point in time and consisted of a 3:1 (MRC-5 
fibroblast to MCF-7 cancerous epithelial) ratio.   
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We believe the responses of fibroblasts that mimic successive stages of tumor-induced stroma 
progression can be used in 3D cultures with epithelial cells in order to study tumor-associated ECM 
induced responses such as growth and cell morphology.  By classifying cultures as having an activated 
or a quiescent reactive stroma, using the mechanobiology profile (stiffness, activation, differentiation, 
and proliferation) we may be able to discriminate between effectiveness of fractionation schemes.       
Our general approach was to first analyze the initial stromal components of the stimulated 3D 
cultures  alone; thus we found this model to be viable to test mechno-environmental changes.  We then 
experimented with 3D co-culture to model residual disease.  This study yields a reproducible system 
developed to co-culture malignant epithelial cells and fibroblast populations in an ECM, thus providing a 
physiologically relevant in-vitro model system to study the role of the microenvironment under breast 
conserving treatment.  This is an important step in acquiring a systems-radiobiology perspective for 
optimizing breast cancer radiation therapy. 
2.2 Radiobiology 
All cancer therapies try to target characteristics that are unique to cancer cells that also 
minimize damage to normal cells.  There are several factors that may affect both normal and cancer cells 
that survive radiation. Normal cells can repair some of the damage caused by the radiation and survive. 
In addition cells going through mitosis are more sensitive and will be more readily killed than those in 
the synthetic phase of the cell cycle (Figure 2) (Schulz 2005).  Cancer cells, being highly proliferative, are 
more likely to be undergoing mitosis, and thus they are more radiosensitive than normal cells. 
Cell cycle and cell death are defined by mitosis (M) where division takes place and synthesis (S), 
the period of DNA synthesis. The M and S phases are separated by two periods G1 and G2 during which 
DNA is not synthesized but other metabolic processes take place. In general, cells are most 
radiosensitive in the M phase and G2 phase and most resistant in the late S phase (Hall 1994). 
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When cells are exposed to IR, bond breaking occurs in one of two ways; directly, by ionization of 
the biomolecule, or indirectly, through the ionization of water and formation of damaging reactive 
radicals.  It is known that the most radiation-sensitive biomolecule in living tissue is DNA (Hall 1994).  
When IR impinges upon an aqueous environment, O-H bonds within water molecules break to form the 
highly reactive •OH. •OH disrupts DNA primarily by abstracting H• at various places on the helix. This 
process leaves behind radical lesions which can form various oxyl and peroxyl radicals by reacting with 
O2 or SO; the resultant peroxides can undergo Fenton type reactions (Bloomer & Adelstein 1982).  
Fenton reagent is a hydrogen peroxide which is used to oxidize contaminants. IR can induce cell-cycle 
arrest.    Normal cells react to DNA damage during drug or radiation therapy by checkpoint activation, 
with cell cycle arrest and resume proliferation (if at all) only after DNA repair is completed. Because of 
defective checkpoint control, cancer cells proceed through mitosis and G1 irrespective of DNA damage. 
This can lead to mitotic catastrophes, mitotic arrest, or to persistent double-strand breaks that elicit 
apoptosis during the next round of replication.  However, while most cancer cells die or arrest, a few 
may escape with severely damaged genomes and increased genomic instability. These are responsible 
for remissions and are usually resistant to treatment.   Checkpoint mechanisms are major determinants 
of the cellular response to radiation. 
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Figure 2 Normal cells react to DNA damage during drug or radiation therapy by checkpoint activation, with cell cycle arrest 
and resume proliferation (if at all) only after DNA repair is completed. Because of defective checkpoint control, cancer cells 
proceed through mitosis and G1 irrespective of DNA damage. This can lead to mitotic catastrophes, mitotic arrest, or to 
persistent double-strand breaks that elicit apoptosis during the next round of replication.  However, while most cancer cells 
die or arrest, a few may escape with severely damaged genomes and increased genomic instability (bottom right). These are 
responsible for remissions and are usually resistant to treatment. 
 
G2 checkpoint protein(s) play a major role in recognizing radiation-induced DNA damage and 
initiating repair responses in the cell. Thus, loss of the G2 DNA damage checkpoint renders lymphoma 
and carcinoma cells more sensitive to the cytotoxic actions of radiation and chemotherapeutic agents.  
DNA damaged cells rapidly enter into mitosis, resulting in further chromosomal damage, chromosome 
loss, and cell death. Radiation damage of DNA is a consequence of cells being radiated.  Cells with 
radiation damaged DNA can try to repair the damage so it is viable once again, however if the repair 
fails, a mutation can lead to cancer. In some cases the DNA damaged cell does not repair and dies (Qin & 
Li 2003). 
Cancer radiobiology is usually the study of damage and repair of clonogenic cancer cells.  Yet IR 
is known to also remodel stroma through production of chemically-reactive oxygen species (ROS) that 
increase ECM cross linking and promote enhanced release of growth factors.  ROS are free-radical 
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molecules (unpaired valence electrons) generated from ionized water that damage cell components as 
they migrate.  ROS are formed slowly during metabolism at a rate that can be scavenged naturally in 
cells by the production of catalase, vitamins, and enzymes, e.g., superoxide dismutase (Rao et al. 2008), 
to mitigate cell damage and genomic mutations.  When ROS is produced in large concentrations by IR, 
however, the antioxidant defenses of cells are overwhelmed, placing them in oxidative stress and 
making them susceptible to extensive damage.  IR can break apart DNA strands directly through charged 
particle ionization, but more common for low Linear Energy Transfer (LET) radiation is ROS damage.  
ROS also stimulates TGF-1 release to induce CAF transitions (Nguyen et al. 2005).  Cell proliferation 
occurs through integrin receptor-tyrosine-kinase signaling.  Simultaneously, TGF-β1 reduces cell 
adhesions and the anchorage-dependent cell growth requirement (Chiarugi et al. 2003).  Interactions 
between the reactive stroma and surviving cancer cells during fractionated IR exposure are important 
understudied factors for RT planning. 
2.3 Radiotherapy treatment fractionation  
The aim of radiotherapy is to deliver enough radiation to the tumor to destroy cancer cells while 
damaging normal tissue as little as possible.  Figure 3 presents the area of optimal dose where the 
tumor receives the greater effect of radiation while the healthy tissue is spared from the lethal effects. 
This is the narrow margin which clinicians need to work with to deliver a safe and successful treatment.  
Though it is difficult to change the sensitivity or resistance of cells, fractionation is employed to achieve 
optimal dosage. 
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Figure 3 The tumor tissue suffers from the radiation dose which is still tolerated by the healthy tissue. The width of the 
window sets the upper and the lower limit for the dose that is applied to the target volume.  Image adapted from 
(Gunderson & Tepper 2007). 
   
Most clinical radiotherapy treatments are not given at one time. In fact, dose fractionation is 
used to deposit a total tumor dose in a number of small fractional doses. This is done to reduce late 
effects to normal tissues while efficient killing tumor cells. 
The basis for fractionation in radiotherapy can be demonstrated through the four R’s of 
radiobiology: repair, re-assortment, repopulation and re-oxygenation (Hall 1994).  Repair is simply the 
restoration of the integrity of damaged macromolecules. Re-assortment is the return of cells towards a 
natural distribution within the cell cycle following the selective killing within certain phases of the cycle.  
Repopulation is the proliferation of clonogenic cells, and reoxygenation is the process by which surviving 
hypoxic clonogenic cells become better oxygenated during the period after irradiation. Fractionation 
helps spare normal tissues through repair and repopulation and increases tumor cell kill due to 
reassortment and reoxygenation (Van Dyk 1999).  Therefore, optimizing the dose fractionation schedule 
to accommodate the various effects becomes an important clinical concern. 
Due to differences in radiosensitivity and sublethal-damage repair rates between cancerous and 
noncancerous cells, dose fractionation parameters are important for maximizing the Therapeutic Ratio 
Tumor control 
Adverse effect 
Tumor 
Healthy tissue 
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(TR), where the limiting factor is the response of noncancerous tissues (patient tolerance).  Fractionation 
schedules are selected to allow time for normal cells to repair radiation damage; cancer cells are less 
efficient at repair (Hall 1994).  The current standard for breast treatment considers patients presenting 
in two stages, T1 and T2.  T1 tumors are 2 cm or less in size and T2 tumors are between 2-5 cm and 
candidates for breast conserving therapy (Kantarjian 2006).   After lumpectomy and lymph node 
sampling, whole breast RT is administered to patients with early invasive breast cancer to decrease 
recurrence rate (Hall 2003).   A common schedule for T1 and T2 lesions is 4500 cGy dose delivered over 
25 fractions at a dose per fraction of 180 cGy (Gunderson & Tepper 2007).  More invasive carcinomas 
may receive a boost dose of an additional 1600 cGy over 8 fractions to the primary site (Holloway et al. 
2010).  Failure of RT to control residual cancer-cell progression in some patients is still a major clinical 
problem (Pinsky et al. 2007).   Our focus is on the response of the cancer cells and the 
microenvironment (reactive stroma) to different fractionation schedules.   
Fractionation schedules are established from dose-survival curve observations (Muriel 2002).  
Treatment parameters (dose per fraction, time between fractions, and total dose) are selected to yield 
the highest patient-tolerated TR.  As we discover more about microenvironmental influences in cancer 
cell biology and as molecular imaging improves our ability to track relevant cellular biomarkers, the 
systems approach to treatment design becomes more realistic.   
Thus breast tumor growth depends on the behavior of cancer cells in their microenvironment, 
and both components are affected by IR fractionation parameters.  Our study reports on the use of 3D 
cell culture model to examine fibroblast cell responses to growth factor stimulation and IR at various 
fraction sizes.  The goal is to characterize how the microenvironment changes with and without IR 
fractions. 
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CHAPTER 3 
STROMAL RESPONSES TO FRACTIONATED RADIOTHERAPY 
 
3.1 Introduction 
The search for optimal radiotherapy fractionation schedules for treating breast cancer, viz., ones 
that minimize breast tumor recurrence following conservation surgery (Marcu 2010), must include the 
influences of the mammary-cell microenvironment that plays a complex and central role in regulating 
tumor growth (Polyak & Kalluri 2010).  Although the primary objective of ionizing radiation (IR) exposure 
is to control growth of cancerous epithelial cells (cancer cells), IR-induced gene expression in cells of 
adjacent stroma also modulates conditions that affect cell growth (Barcellos-Hoff 2008, 2010).   Stroma 
includes fibroblast, macrophage, lymphocyte, and endothelial cells, although fibroblasts are the most 
abundant and active during malignant tumor growth.  IR prompts release of TGF-1 that directs the 
differentiation of fibroblast cells to further increase growth factor expression in a positive feedback 
manner (Herskind & Rodemann 2000).  This process stiffens the peri-epithelial ECM that encourages 
cancer cell growth (Levental et al. 2009; Shieh 2011).  While the balance of pro- and anti-tumorigenic IR 
responses favors the latter, the margin is small such that optimal IR fractionation in adjuvant 
applications involves a careful balance among several competing factors.   
Normal adult female glandular breast tissues are remodeled cyclically in response to systemic, 
paracrine, and autocrine cell signaling (Bissell 2006).  Homeostasis depends in part on the ability of 
stromal cells to sense their microenvironment and respond by producing soluble and insoluble proteins.  
Fibroblast cells excrete insoluble proteins including collagen and glycoproteins that constitute the ECM.  
The ECM is the substrate that gives glandular tissues their mechanical properties and enables cell 
 25 
 
movement.  Integrin receptors found in cell membranes coalesce to form focal adhesion points that, 
once attached to ECM glycoproteins, enable cells to move while sensing the stiffness of their local 
matrix.  Cells move by adjusting cytoskeletal tension in proportion to forces sensed by their integrin 
receptors.   
Cancer cells in a stiff matrix display malignant features; e.g., disrupted adheren junctions, lost 
polarity, and enhanced proliferation rates (Paszek et al. 2005).  They release growth factors that activate 
the differentiation of adjacent fibroblasts into cancer associated fibroblasts (CAF), or myofibroblasts, 
through wound healing mechanisms (Eck et al. 2009).  The enhanced α-SMA increases the ability of CAFs 
to generate large contractile forces, further stiffening the matrix and promoting further expression and 
release of TGF 1.  Cancerous epithelial cells can themselves transition into mesenchymal cells through 
epithelial-mesenchymal transition (EMT), including CAFs, as a result of growth factor signaling (Petersen 
et al. 2001).  Thus CAFs alter the chemo-mechano-environment of surrounding cells to favor pro-
tumorigenic conditions.   
Primary malignancies grow quickly once epithelial cells from in situ disease invade the peri-
ductal stroma and are able to communicate directly with mesenchymal cells.  Responding to limited 
resource challenges, cancer cells cooperate with mesenchymal cells to remodel the stromal 
microenvironment, in part, to build the vascular infrastructure necessary to sustain tumor growth 
(Weinberg 2007).  Heterotypic signaling results in a reactive stroma characterized by inflammatory 
responses that stimulate fibrosis, neoplasia, edema, desmoplasia, as well as angiogenesis; each 
response increases tumor mass stiffness as cancer cells in the reactive stroma proliferate.  At the heart 
of cancer progression is growth factor signaling of fibroblasts, their differentiation to CAFs and 
concentration at the margins of the developing solid tumor.  TGF-β1, a product of both CAFs and cancer 
cells, plays an important dual role during carcinogenesis.  In normal breast tissues and during the early 
 26 
 
stages of tumor development, TGF-β1 suppresses growth.  During later stages, however, it favors pro-
tumorigenic and metastatic activities (Kalluri & Zeisberg 2006).  TGF-β1 is a powerful stimulant of 
stromal tissue responses that lead to changes in the cellular mechanoenvironment.   
Despite considerable advancement in tumor biology, the primary curative treatments for breast 
cancer continue to be surgery, chemotherapy, and radiation therapy (RT) (Nemade 2008).  Combinations 
of these three, which increasingly include endocrine and/or growth-factor inhibition adjuvants, have 
been found to significantly extend progression-free survival (Johnston 2009).  We are investigating 
photon RT applied as an adjuvant treatment following breast-conserving surgery and in the context of 
stromal-cell biology.  We are using a fibroblast-cell culture model to understand the interactions 
between IR and stroma in creating mechano-environments that can affect the cancer cell-to-noncancer 
cell therapeutic ratio (TR) during fractionated RT.   
Thus breast tumor growth depends on the behavior of cancer cells in their microenvironment, 
and both components are affected by IR fractionation parameters.  Our study reports on the use of 3-D 
cell culture model to examine fibroblast-cell responses to growth factor stimulation and IR at various 
fraction sizes.  The goal is to characterize how the mechanical environment changes as MRC-5 
fibroblasts become activated by TGF 1 with and without IR. 
3.2 Materials and Methods 
Three-dimensional collagen matrices are frequently used to isolate and model the behavior of 
various mammary cell types (Olsen et al. 2010).  We adopted a system composed of human fibroblast 
cells embedded within a collagen I matrix to study two effects of varying fractionation size on the 
cellular microenvironment – fibroblast activation (i.e., transformation to myofibroblast cells) and matrix 
stiffness.  This section describes our measurements of collagen-matrix stiffness and fibroblast-cell 
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differentiation ratios in 3-D culture samples undergoing TGF-β1 stimulation following various IR 
exposures.   
3.2.1 Cell cultures 
Human lung fibroblast cells (MRC-5) purchased from American Type Culture Collection (ATCC, 
Rockville, MD, USA) were cultured in 75 cm2 tissue culture flasks with Minimum Essential Medium Eagle 
(MEME, Invitrogen, Carlsbad, CA) to which 10% fetal bovine serum (FBS, Sigma, St. Louis, MO, USA)  and 
1% pen/strep (Sigma) were added.  Cells were incubated at 37°C, 5% CO2, propagated to 80-90% 
confluence, and harvested with 0.25% trypsin/1mM EDTA (disodium ethylenediamine tetraacetic acid, 
GIBCO, Carlsbad, CA, USA)  that was neutralized with 10% FBS MEME.  Cell passage numbers were 
between 5 and 12.   
Culture matrices were prepared from a commercial type I collagen stock solution (10 mg/ml, rat 
tail, BD Biosciences, Bedford, MA, USA).  Collagen solutions were diluted and neutralized with medium 
and 1N sodium hydroxide to 2.0 mg/ml.  If cells were introduced to a particular sample, it occurred at 
this time.  600 µl volumes of collagen solution were dispensed to a 48-well plate and incubated at 37°C 
as the collagen polymerized over 30 min.  After polymerization, 300 µl of complete MEM was applied to 
the top of the gelled samples.  With or without cells, the total fluid volume added to each sample was 
600 µl so that matrix stiffness was not influence by medium volume.   
To select a cell density for the 3-D collagen-culture samples, an initial study was performed in 
which fibroblasts were added to the collagen solution at five different densities: 10,000, 50,000, 
100,000, 250,000, and 500,000 cells/ml.  At low densities (10,000 and 50,000 cells/ml), cells did not 
thrive.  At high densities (250,000 and 500,000 cells/ml), many gel samples shrunk substantially as 
growth-factor stimulated cells to contract until the gel was pulled from the walls of the well.  We used 
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200,000 cells/ml throughout the study, because at this density cells thrived without gel samples 
changing shape or collapsing.   
Within the collagen matrix, fibroblast activation (differentiation to myofibroblasts) was 
intentionally promoted by first incubating samples as described above for 24 hours, then replacing the 
growth medium with low serum-media to starve cells overnight, and finally replacing the low-serum 
medium with 10 ng/ml TGF-β1(Sigma) in 0.5% FBS/MEM.  TGF-β1 was applied in a single treatment 
application prior to the irradiation.  Because the density of collagen-matrix cross links increase over time 
even without cells or irradiation, and since matrix tension develops as embedded cells contract, the 
stiffness of all samples increased over time.  Matrix stiffness increased further depending on cell number 
and on processes that modify matrix cross linking or fibroblast differentiation; both are in flux following 
TGF-β1 introduction or sample irradiation.  We experimented with different TGF-β1 concentrations in 
the range of 0.10–10 ng/ml and measured the cell activation that resulted (Xu 2010).  From the 
activation data in Figure 4, we chose to apply a TGF-β1 concentration of 10 ng/ml to all samples in this 
study.  This concentration consistently induced a repeatable and measurable range of cell activation 
ratios within 24 to 72 hours.   
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Figure 4 MRC-5 fibroblast cell activation ratio is plotted as a function of time for TGF-β1 concentrations between 0.1 – 10.0 
ng/ml.  A ratio of one means all cells are activated in a sample.  Activation is determined from the mean fluorescence 
intensity of α-SMA of three sample regions within several sample layers using confocal microscopy.  Error bars indicate ±1 
standard error.  Experimental data are fitted to a three-parameter logistic function assuming activation over time for a fixed 
amount of growth factor is modeled as population growth.  The three parameters are maximum activation ratio, activation 
rate, and carrying capacity.  Reprinted with appropriate permission obtained from (Xu 2010). 
 
3.2.2 Sample groups 
Our current study consists of 6 groups of samples: collagen-only gel control (Group 1), irradiated 
collagen-only gel (Group 2), collagen plus MRC-5 fibroblast cells (Group 3), irradiated collagen with MRC-
5 cells (Group 4), collagen plus MRC-5 cells stimulated by TGF-β1 (Group 5), and irradiated collagen with 
MRC-5 cells stimulated by TGF-β1 (Group 6).  Although the initial cell density in each sample was 
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200,000 cells/ml, the density of living cells changed over the experiment time depended on the group as 
described in Figures 11 and 12. 
3.2.3 Sample irradiation  
Samples were irradiated by placing them in a 6 MV (million electron volt) photon field generated 
by a linear accelerator (Varian Medical System, Palo Alto, CA, USA).  A uniform dose was delivered with 
the gantry set to 0 degrees and with a 100 cm source-to-axis distance.  An 8 x 8 cm2 field size was 
selected to ensure cell culture samples were uniformly irradiated (Figure 5).  Dosimetric-quality solid 
water was placed above and below the well plates to provide proper build-up dose.  All samples were 
taken from the incubator and placed in a thermally isolating container for transportation to the clinic.  
Once removed from the container, samples were exposed to IR at room temperature in a single dose 
and returned to the incubator within 30 minutes.   The standard clinical dose fraction for breast 
treatment of 180 cGy was delivered to samples at a rate of 400 cGy/min.  Other samples were exposed 
at the same dose rate but at a reduced fraction of 90 cGy or an accelerated fraction of 360 cGy.  All 
sample irradiations were delivered in three fractions, once each 24 hours over three consecutive days, 
so the total dose was 270, 540, or 1080 cGy. This dose was experimentally verified using an ionization 
chamber (Exradin Model A12).  Experimental setup was scanned using computed tomography unit 
(Brilliance CT, Philips) (Figure 6) and imported into Radiation Treatment planning software system 
(Philips Pinnacle3 System, Madison, WI) for dose delivery verification (Figure 7).   
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Figure 5 Varian Clinac with our experimental setup.  (Inlet): The 48 well plate was placed on a 5 cm tissue equivalent material 
(TEM).  Above the well plate was a 1cm bolus plus a 1 cm of TEM to provide proper build-up dose.  Samples were irradiated 
by placing them in a 6 MV photon field generated by accelerator.  A uniform dose was delivered with the gantry set to 0 
degrees and with a 100 cm source-to-axis distance.  An 8 x 8 cm
2
 field size was selected to ensure cell culture samples were 
uniformly irradiated. 
 32 
 
 
Figure 6 Experimental set-up was scanned using a Philips Big Bore CT to be imported into treatment planning system for dose 
computation. 
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Figure 7 CT scan imported into Philips ADAC Treatment planning system to verification dose distribution for fractionated 
studies.  The software simulated the set on the Clinac to deliver the prescribed fraction to be delivered at a rate of 4 Gy/min 
(Please reference Appendix B for details on designing a treatment plan). 
 
3.2.4 Mechanical testing 
Within 1 hour following delivery of the last fraction, samples were mechanically tested using a 
TA.XT Plus Texture Analyzer System with a 1 kg load cell (Texture Technologies Corp., Scarsdale, NY, 
USA) and a compressive indentation procedure.  The experimental protocol is the same as that used in 
our lab’s earlier studies on gelatin hydrogels (Kalyanam et al. 2009).  The fluid medium was removed 
from the top of the sample before testing with a 5-mm-diameter spherical indenter.  The indenter was 
pressed into the sample surface at low velocity, 10-1 mm/min and to a depth of 2.5 mm (Figure 8).  Force 
(F) and displacement (d) were recorded by the instrument to estimate sample stiffness.    
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An indentation rate of 10-1mm/min was used to minimize poroelastic responses due to fluid flow within 
samples.   Though indentations were performed to depths up to 2.5 mm, the mechanical stiffness was 
measured from the slope of the force-displacement curve in the range 0 < d < 0.5 mm where the curve is 
approximately linear.  The slope was converted to stiffness k measured in Newtons/meter (N/m) as 
shown schematically in Figure 8.  Although k is not an intrinsic property of the material, it may be 
considered as a relative stiffness modulus since the geometry of all samples in the study is identical.  
One stiffness measurement was made for each sample during the first force-displacement cycle.  The 
stiffness values shown in the results below are an average of measurements from 4 or 6 samples, as 
indicated in the figure captions.   
 
Figure 8 (left) Indentation measurement of the mechanical stiffness of 3-D collagen-matrix cell cultures is illustrated.  (right) 
Force-displacement plots show how the force F sensed by the indenter varied with indenter depth d during loading and 
unloading phases. Stiffness k is defined by the slope F(d)/d near d=0.  Reprinted with appropriate permission obtained from 
Informa Healthcare. 
 
3.2.5 Immunofluorescence staining 
Activated cells were identified based on their appearance following alpha-smooth muscle actin 
(α-SMA) targeted immunofluorescence staining.  The total number of cells in the field was determined 
based on TO-PRO 3 (TO-PRO®-3 iodide (642/661)* 1 mM solution in DMSO (dimethylsulfoxide, 
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Molecular Probes, Inc., Eugene, OR, USA) nuclear staining. The fraction of activated cells was 
determined from the number expressing high levels of α-SMA divided by the total number of cells. 
Following mechanical testing, collagen samples were fixed as follows.  Samples were washed with 
Phosphate-Buffered Saline (PBS, Lonza, Wackersville, MD, USA) before being fixed with 4% 
paraformaldehyde at 4°C overnight.  Samples were then washed and permeabilized in 0.02% Triton X-
100 in PBS for 15 mins followed by 5% non-fat milk blocking for 2 hours. Gels were then incubated with 
primary antibody, consisting of Bovine Serum Albumin (BSA, Sigma), PBS and Tween 20 (T, Sigma), 
(1:100 in 1% BSA/PBS/T) overnight at 4°C and secondary antibody (1:200 in 1% BSA/PBS/T) at room 
temperature for 2 hours. Cell nuclei were stained with TO-PRO 3 (1:1000 in PBS) for 20 mins.  Sections 
were mounted between two glass coverslips with anti-photobleaching reagent.  
3.2.6 Confocal microscopy  
Immunofluorescence-stained samples were examined with a Leica SP2 laser scanning confocal 
microscope (Leica, Heidelberg, Germany) with Hg lamp and helium/neon laser and the associated 
software (Leica Confocal Software Version 2.00).  A 488 nm excitation wavelength was applied for 
Fluorescein isothiocyanate (FITC) mapping, and a 633 nm excitation wavelength was used to find nuclei 
via TO-PRO 3 mapping.  For each sample, a 20X objective captured a series of images along the z-
coordinate (sample depth) at 3-5 μm increments.  For confocal microscopy, an imaging system was 
employed (Microradiance; Bio-Rad, Philadelphia, PA, USA) consisting of a 25-mW argon ion laser 
emitting at 488 and 514 nm and a 1-mW green helium–neon laser emitting at 546 nm attached to a BX-
50 microscope (Olympus Imaging America, Inc., Center Valley, PA, USA).   
3.2.7 Automated cell counting 
Activated fibroblasts are characterized as cells expressing large amounts of intracellular α-SMA 
as visualized using immunofluorescence imaging techniques.  Confocal imaging yielded 40 images from 
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adjacent planes of each sample from which cells were counted to determine activation fractions.  An 
automated segmentation method was developed to identify and count activated cell bodies and all cell 
nuclei from each confocal image.  Counted cells had intensity and shape information at or above 
threshold values as specified in an image analysis program.   
The threshold values adopted were those providing consistent cell counts that correlate with 
visual counting tests on the same images.  We visually counted nuclei and cell bodies in many images 
several times, e.g., see Figure 9, and found it was straightforward to consistently identify the number of 
activated cells based on the appearance of green-fluorescent cell bodies showing large levels of α-SMA.      
The intensity level of the cell-counting algorithm was adjusted to be consistent with estimates 
made by visual counting.   Similarly, the algorithm threshold was adjusted for the red-fluorescent 
nucleus so that the algorithms gave mean counts consistent with visual counts.  To avoid double 
counting activated cell bodies in images from adjacent confocal planes, we only counted as active MRC-
5 fibroblasts those cells where a green-fluorescent (GF) cell body and red nucleus (RN) were both super-
threshold and spatially coincident (cf. Figure 8c).  Please see Appendix A section 1 for a detailed 
description of how this was done. 
 
Figure 9 Automated cell counting using fluorescent images of fibroblasts is outlined.   (a) Confocal fluorescence microscopy 
images (20×) indicate the α-SMA content of individual fibroblasts (green) and associated cell nuclei (red).  Green cell bodies 
(b) that m meet intensity threshold criteria (c) are counted as activated. A similar method was used to identify cell nuclei 
from red fluorescence images (not shown).  The number of supra-threshold red nuclei indicates the total number of cells 
(activated and not activated) in the confocal plane.  The number of red nuclei found within a green fluorescent cell body, 
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which both meet the criteria, indicate the number of activated fibroblasts (myofibroblasts) in the same confocal plane.  
Reprinted with appropriate permission obtained from Informa Healthcare. 
 
3.2.8 Statistical analysis 
Three-way analysis of variance (ANOVA) was performed using R software to determine the 
significance of differences at a  = 0.05 level among mean stiffness and activation measured for the 
various collagen samples.  The input parameters were (a) culture condition (collagen matrix alone, 
collagen with MRC-5 fibroblast cells, and collagen with TGF-β1 activated MRC-5 fibroblasts), (b) culture 
age, and (c) ionizing radiation dose.  Observed differences among mean sample stiffness for sample 
groups were evaluated with post-hoc analysis, including Tukey HSD (honestly significant difference) 
(Calinski 1981). 
3.3 Results 
In the results presented below, the stiffness of the collagen matrix, the total number of MRC-5 
fibroblast cells in a 1 ml collagen sample, and the fraction of activated MRC-5 fibroblasts are reported as 
functions of culture condition (matrix only, matrix with cells, and matrix with cells stimulated by growth 
factor), culture age, and radiation fraction size.  The results are focused on differences between 
different classes of samples to demonstrate responses.  Therefore, it’s important to discuss statistical 
analysis to state significance.   
3.3.1 Statistics Result 
For stiffness we found that culture condition, culture age and radiation dose each had a 
significant effect on matrix stiffness (p-value < 0.01). We also found a significant interaction between 
culture condition and radiation dose, culture condition and culture age, and culture condition, radiation 
dose and culture age (p-value < 0.01).  However, no significant interaction was detected between 
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radiation dose and culture age (p-value > 0.05).  Significant interaction indicates the groups together had 
an impact on stiffness.   
For activation we found that culture condition, culture age and radiation dose has a significant 
effect on activation of fibroblasts (p-value < 0.01).  We also found a significant interaction between 
culture condition and radiation dose, culture condition and culture age, radiation dose and culture age 
and culture condition, radiation dose and culture age (p-value < 0.01). 
3.3.2 Irradiation of collagen matrix  
During the first study, we measured the stiffness of collagen samples made without cells for the 
matrix-only control Group 1.  We also measured the stiffness of irradiated matrix-only samples, Group 2.  
These data are reported in Figure 10.  The goal was to observe the effects of age and dose fraction on 
the matrix stiffness without the influence of fibroblast cells.  Without irradiation, Group 1 samples 
stiffened measurably over three days.  After irradiation, Group 2 samples showed the same pattern of 
time-dependent matrix stiffening, while the overall stiffness scaled with radiation dose.   
 
Figure 10 Measured stiffness of collagen gel samples (Groups 1 and 2) formed without cells are shown as a function of three 
daily IR fractions of 6 MV photons and at the three times indicated.  Each data bar results from measurements on N=6 
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samples (mean ± 1 SE).  No radiation was given to the control samples.  * indicates statistical significance at the p < 0.05 
level.  Reprinted with appropriate permission obtained from Informa Healthcare. 
The observed sensitivity of matrix-only samples to radiation is expected, given that IR produces 
reactive oxygen species (ROS) that chemically react with collagen molecules to cross link and stiffen 
matrices.  It was proposed that cross linking occurs through energy absorption by aromatic groups 
within the collagen molecules (Gouk et al. 2008).  Although x-rays also degrade collagen through 
peptide-bond cleavage, increased collagen cross linking dominates because the high water content of 
samples generates a large concentration of free radicals (Barcellos-Hoff & Dix 1996; Nguyen et al. 2005).   
The initial production of radicals and their reaction with surrounding molecules stiffens the matrix 
instantaneously following irradiation.     
3.3.3 Irradiation of MRC-5 fibroblasts in collagen matrix  
During the second study, summarized in Figure 10, we measured cell activation and stiffness for 
sample Groups 3 and 4.  These samples were also 3-D collagen matrices but with cells embedded and no 
added growth factors.  They were irradiated over time in the same manner as Groups 1 and 2.  The 
presence of cells initially softened the matrix by approximately 40% (Group 3 in Figure 11a) as compared 
with matrix-only samples (Group 1 in Figure 9), but matrix stiffness rose to recover after 72 hours.  Cell 
numbers nearly doubled in samples over 72 hrs (Group 3 in Figure 11b), but few of the cells (< 10%) 
were activated (Group 3 in Figure 11c).  Thus we attribute Group 3 sample stiffening seen in Figure 10a 
primarily to aging of the collagen matrix.   
Irradiation at a 90 cGy fraction stiffened Group 4 (Figure 11a) samples significantly after one 
dose fraction at 24 hours, but there was no significant increase in stiffness after 48 hours (2 fractions) or 
72 hours (3 fractions).  The increase in stiffness mirrors the increase in cell density and activation ratio at 
90 cGy, suggesting that larger numbers of activated fibroblasts are responsible.  Increasing the IR 
fraction size to 180 or 360 cGy initially stiffened the matrix further as it activated larger fractions of 
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fibroblasts, but dose fractions delivered in subsequent days did not further stiffen samples as it did for 
matrix-only samples.  The presence of cells seems to buffer the time-varying effects of radiation.  At 
higher doses, cells are not proliferating and activation is decreasing over time as cells die off.  Note that 
nuclear staining identifies all cells present at the time of preparation, dead or alive, so cell number 
cannot decrease over the 3-day observation time.  The images inset in Figure 11c are examples of cell 
culture imaged at 48 hours for a Group 3 sample and a Group 4 sample following two 180 cGy fractions.  
Images show 8% and 18% activation, respectively.  Figure 11 (cont. on next page). 
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Figure 11 Measurements of sample stiffness (a), total cell number per sample (b), and cell activation ratio (c) for collagen gel 
samples (Groups 3 and 4) formed with fibroblast cells and without TFG-β1.  Group 4 samples are given three daily IR fractions 
at the three times indicated. Each bar in the stiffness results is taken from measurements on N=6 samples (mean ± 1 SE).  Cell 
numbers (b) and activation ratios (c) are for N=4 samples. No radiation was given to the control samples.  * indicates 
statistical significance at the p < 0.05 level.   INSET: IHC-stained confocal fluorescent images for (i) a non-irradiated sample 
and (ii) a sample irradiated with 2 fractions of 180 cGy.  Both samples were imaged after 48 hours.  Reprinted with 
appropriate permission obtained from Informa Healthcare. 
 
Consistent with the findings of others (Herskind & Rodemann 2000), irradiation initially 
activated fibroblast differentiation to myofibroblasts.  One mechanism might involve autocrine TGF-β 
loop signaling (Ronnov-Jessen et al. 1996).  Others (Herskind & Rodemann 2000) found that the amount 
of TGF-β1 released per cell increased in radiated cultures.  TGF-β1 may also increase through activation 
of latent TGF-β1 stored in serum.  Thus TGF-β1 is a likely mediator of radiation-induced differentiation 
(Hakenjos et al. 2000).  Dose-dependent activation of latent TGF-β1 has been observed at doses as low 
as 10 cGy and attributed to ROS activity (Barcellos-Hoff & Dix 1996; Rave-Frank et al. 2001).  Radiation 
induced ROS production is known to have important effects on cell-cycle progression and differentiation 
(Storz 2005), which may factor into the changes in matrix stiffness seen in Figure 10 for different fraction 
sizes.  This mechanism involves the activation of specific proteolytic enzymes from inactive proenzymes 
and is most likely dependent on the presence of ROS. Scavengers of radiation-induced free radicals or 
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ROS, such as amifostine, can inhibit ROS-induced activation of latent TGF-β (LTGFβ) as well as diminish 
the plasma level of TGF-β1(Rodemann & Blaese 2007). 
3.3.4 Irradiation of MRC-5 fibroblasts stimulated by TGF-β1 in collagen matrix  
During the third study summarized in Figure 12, we measured cell activation and stiffness for 
sample Groups 5 and 6.  As in the previous study, samples were composed of a 3-D collagen matrix with 
interspersed fibroblasts, but these cells are activated by 10 ng/ml TGF-β1.  As in the other studies, 
samples were irradiated over time at different dose fractions.  TGF-β1 stimulated cells that were not 
irradiated (Group 5 in Figure 12) were almost fully activated (90%) in two days, producing a matrix 
nearly four-times stiffer after 72 hrs.  However, irradiation reduced cell-generated matrix stiffness and 
fibroblast activation even as the cells continued to slowly proliferate over three days.  We found that 
cell proliferation and activation decreased or remained the same with increasing fraction size, while 
sample stiffness increased marginally.  Observed stiffness changes caused by fraction size were minimal.  
Despite a stiffening matrix, larger fraction sizes do not appear to significantly promote a reactive stroma, 
at least for these isolated model components.  Figure 12 (cont. on next page). 
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Figure 12 Measurements of sample stiffness (a), total cell number per sample (b), and cell activation ratio (c) for collagen gel 
samples (Groups 5 and 6) formed with fibroblast cells that were stimulated by 10 ng/ml TFG-β1.  Group 6 samples were given 
three daily IR fractions at the three times indicated.  Each bar in the stiffness results is taken from measurements on N=6 
samples (mean ± 1 SE).  Cell activation and number results are for N=4.  No radiation was given to the control samples.  * 
indicates statistical significance at the p < 0.05 level.  INSET: IHC-stained confocal fluorescent image, showing α-SMA in green 
and nuclei in red, for a sample irradiated with one fraction of 90 cGy.  The measured activation ratio is 43%.  Image is at 20X 
magnification.  Reprinted with appropriate permission obtained from Informa Healthcare. 
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3.4 Discussion 
The results above describe the responses of isolated 3-D cultures of fibroblast cells stimulated 
by a growth factor and ionizing radiation.  We measured three output variables to describe the 
environment that would surround cancer cells if they were present. However, this analysis was focused 
on two variables, collagen matrix stiffness and fibroblast activation, since our interest is in the 
mechanobiology of the breast tumor environment.  The addition of TGF-1 was meant to simulate one 
important consequence of the heterotypic signaling that occurs between cancerous epithelial cells and 
fibroblasts during tumorigenesis (Weinberg 2007).  To discuss these multifactorial results, we recombine 
the raw data from Figures 10-12 in Figures 13-15 so that we may draw attention to various elements. 
Figure 13 displays results from all groups of samples, although we fixed two of the input 
variables to show results after 72 hrs and for 180 cGy/fraction.  Without irradiation (solid curve, 
control), there were 4x105 fibroblast cells per ml present.  Yet they affected the matrix stiffness very 
little because without growth factor stimulation only about 10% of cells were converted to 
myofibroblasts.  Simulated by TGF-β1, however, the same fibroblast density is 90% activated, which 
triples the matrix stiffness as myofibroblast cells are able to attach to the matrix and contract.  Since the 
interaction between cancer cells and fibroblasts promotes the release of growth factors (Eck et al. 
2009), fibroblast activation further increases growth factor production and matrix stiffening, which sets 
up a positive feedback loop promoting tumor growth (Petersen et al. 2001).   
However, irradiating the same sample types (Fig 13, dashed curve) shows a very different 
stiffness pattern.  Chemical cross linking in the cell-free matrix induced by three fractions of 180 
cGy/fraction greatly stiffens the matrix.  The presence of cells mitigates stiffening even if the cells are 
stimulated by growth factor.  Although 45% of the fibroblasts were activated by growth factor compared 
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to just 10% without growth factor, the radiation has either reduced the total cell population or 
prevented viable cells from attaching to the matrix such that the matrix remains soft.   
 
Figure 13 The behavior of all six study groups is shown for samples measured at 72 hrs and at 180 cGy/fraction. These data 
are replotted from Figs 9-11.  Reprinted with appropriate permission obtained from Informa Healthcare. 
 
If we focus just on activated fibroblast samples, we may observe the effects of irradiation in 
Figure 14, where sample stiffness is plotted as a function of cumulative dose for Groups 5 and 6.  
Without irradiation (control group), cells act to triple the stiffness of the matrix.  With irradiation, 
however, there is a modest increase in stiffness with dose.  Larger fraction sizes double matrix stiffness 
through a combination of collagen cross linking and enhanced fibroblast activation, but as dose 
accumulates the net effect keeps the stiffness less than that occurring without irradiation.   
 46 
 
 
Figure 14 Matrix stiffness data from Groups 5 and 6, containing TGF-β1-stimulated fibroblasts, are plotted versus cumulative 
radiation dose over 72 hrs.   Error bars indicate one standard error of the mean (SEM).  Reprinted with appropriate 
permission obtained from Informa Healthcare. 
 
So we see from Figures 12 and 13 that irradiating the matrix without cells will significantly 
increase stiffness.  Allowing stimulated fibroblasts to grow also increases stiffness, and a stiff matrix in 
the presence of growth factor generates a reactive stroma that promotes tumor growth (Barcellos-Hoff 
2010).  However, combining these elements by irradiating stimulated fibroblasts, we find a moderate 
increase in matrix stiffening.   
In Figure 15, we plot two of the output variables against each other, matrix stiffening and 
fibroblast activation, to show how radiation fraction size reduces the reactive stroma required for tumor 
progression.  Curves are generated by plotting data obtained over three time points, although time is 
not explicitly indicated.  The control group in this plot consists of non-irradiated samples with fibroblasts 
not stimulated with growth factor.  This represents a normal-tissue condition, and we find that all of 
these data points reside in the lower left corner.   
 47 
 
 
Figure 15 (top) Elements that contribute to a reactive stroma, which is an important for cancer cell proliferation and tumor 
growth.  (bottom) Stiffness measurements and plotted versus activation ratio from the data of Figs 4-6, where the most 
reactive stroma is found for stiff matrix with highly activated fibroblasts.  Reprinted with appropriate permission obtained 
from Informa Healthcare. 
Stimulating the fibroblasts with growth factor without irradiation (labeled TGF-1) shows that 
cells become almost entirely activated before contracting to stiffen the matrix.  This curve represents 
the matrix condition in the presence of untreated cancer cells, which quickly generates features of a 
reactive stroma.   
Finally irradiating stimulated cells with different fraction sizes prevents a reactive stroma but it 
influences the two output variables in different ways.  The smaller fraction allows more fibroblasts to 
convert to myofibroblasts before a reduction in cell number ultimately reduces activation.  Larger 
fraction sizes maintain a low activation ratio but quickly and significantly stiffen the matrix.  So fraction 
size affects these two features of a reactive stroma differently.  If it is more important to reduce 
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fibroblast activation than matrix stiffness, then larger fractions are recommended.  However large 
radiation dose fractions will quickly cross link the collagen matrix to stiffen the matrix.  If stiffening is the 
dominant factor in the reactive stroma promoting cancer cell progression, then smaller fractions are 
recommended.   
Optimization of fractionation size differs for each tumor. A given radiation dose results in 
nonrepairable and repairable damage to tissue.  The ratio of these two parameters differs by tumor 
type.  If the ratio of non-repairable to repairable damage for a tumor is similar to or less than that of the 
surrounding normal tissue, then a larger dose per fraction (hypofractionation) to a lower total dose 
should be the most effective balance of benefits and harms.  Recent clinical investigations indicate that 
this is true for breast cancers (Owen et al. 2006; Abram et al. 2008; Prosnitz et al. 2009).  The 
Standardization of Breast Radiotherapy (START) Trials, which have looked at late adverse effects and 
tumor control, strengthen evidence in favor of alternative fractionation schemes, e.g, hypofractionated 
regimens, with potential for fewer adverse effects to normal breast tissues (Abram et al. 2008).  A 
similar conclusion was drawn by a Cochrane review (James et al. 2010). 
The data presented in this study have the advantage of being from a well-defined culture 
medium that includes essential stromal-cell elements that are involved in breast tumor development.  
Isolating tissue elements allows us to study their responses without the myriad other influences 
normally present in vivo.  The disadvantages of isolated cell preparations are the same as for all cell 
culture studies: isolated elements do not recognize the full extent of systemic influences that lead to 
tumor formation and responses to therapy.  Nevertheless, we see that through a series of cell culture 
and co-culture studies, with increasingly realistic elements that build systemic complexity, we and 
others can discover how to combine the input parameters available to radiation therapists to maximize 
the therapeutic ratio. 
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CHAPTER 4 
STROMAL-EPITHELIAL DYNAMICS IN RESPONSE TO FRACTIONATED 
RADIOTHERAPY 
 
4.1 Introduction 
One of the major challenges in the successful treatment of breast cancer is the effective 
application of adjuvant therapies. Unfortunately the heterogeneity of breast cancer results in a wide 
range of sensitivities and even resistance to existing therapies.  Stromal cells in tumors were thought to 
be merely remnants of tissue among which the cancer cells grew.  We now have evidence that 
heterotypic signaling exists in the tumor microenvironment, by which cells encourage or limit the 
growth of other types of cells in the area.  Although the heterotypic interactions between fibroblasts, 
ECM, and cancerous epithelial cells are being studied by our group and others, it is unclear how the sum 
of these interactions determines the tumor outcome under therapies.  Differences in radiosensitivity 
and sublethal-damage repair rates between cancerous and noncancerous cells, dose fractionation 
parameters are important for maximizing the TR, where the limiting factor is the response of 
noncancerous tissues (patient tolerance).  Thus evaluating alternative radiotherapy techniques on a 
subset of residual disease conditions for early stage breast cancer has the potential for identifying more 
effective and less toxic treatments.    
It is well-established that the tumor microenvironment plays a role in promoting or suppressing 
cancerous phenotypes in epithelial cancers. These thoughts have led to a paradigm shift in the way that 
researchers work with cell culture, moving towards studying cells in more physiologically-relevant 3D 
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environments. Co-culture with cell types present in the microenvironment, including cancer-activated 
fibroblasts (CAFs), are known to change cancer cell behavior.  Paracrine communication between CAFs 
and neighboring cancer epithelial cells is a crucial factor for the continued growth of the tumor mass 
(Sotgia et al. 2009). The tumor microenvironment also plays a role in resistance to radio/chemotherapy 
(Andre et al. 2010).   This makes CAFs key player(s) in tumor progression, invasion, and metastasis 
(Pavlides et al. 2012).  With this understanding, we proposed that contact with CAFs also modulate the 
behavior of cancerous epithelial cells.  Although the system we use is that of the mammary gland, we 
expect that general principles emerging from these results will apply to carcinomas from other tissue 
types as well. 
The reactive stroma contributes to tumor growth via multiple factors. This occurs at the level of 
molecular cross-talk between epithelial cells and fibroblasts via the diffusion of soluble growth factors as 
well as the epithelial cells that are responding to changes in mechanical forces due to CAFs stiffening the 
matrix, upsetting tensional homeostasis.  Apart from cell survival, other parameters such as metabolic 
activity of surviving cells are relevant to assess the effectiveness of radiotherapy.  We tested the 
metabolic activities with the MTT assay of MCF-7 cancer cells, MRC-5 fibroblast and CAFs to improve our 
understanding of the metabolic activity of these cells in terms of their radiobiological functions during 
the course of radiotherapy.     
MCF-7 cancer cells are a commonly used breast cancer epithelial cell line.  They are Estrogen 
receptor – α positive (ER +) and extensively used to model cancer in 3D cultures.  They were derived 
from a pleural effusion (that they were metastatic in the patient from whom they were derived); 
however when injected into animals they do not metastasize, and they can be thought of having a 
“milder” cancerous phenotype than other breast cancer cells lines.  This property fits well with our 
residual disease model for early stage breast cancer.  
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MRC-5 Fibroblasts, when exposed to cancerous stimuli either through treatment with TGF-β1 or 
contact with cancerous epithelial cells (Tsuchiya et al. 2003; Qayyum & Insana 2012b) become 
myofibroblast. This transition is also associated with a stiffening of the local microenvironment in 3D 
culture and in tissue. Thus, it is possible that CAFs, via alteration of their microenvironment, may 
regulate epithelial cell populations through mechanical forces.  Mixtures of MCF-7 cancer cell and MRC-
5 fibroblast will be incorporated into type I collagen gels, and mechanical indentation tests will be 
performed in order to determine the stiffness. 
Fibroblasts are the predominant cell type that comprises the microenvironment of solid tumors; 
they regulate mechanical and chemical homeostasis. When exposed to factors secreted by cancer cells, 
they undergo a fibroblast-to-myofibroblast phenotypic change, characterized by elevated expression of 
α-SMA. CAFs have been shown to enhance cancerous phenotypes in the progression of disease models 
and are associated with poor prognosis in patients (Hellevik et al. 2012).  Here we show that CAFs 
enhance epithelial proliferation by creating a pro-inflammatory (wound healing) environment.   
Using 3D in-vitro models of the breast tumor microenvironments after lumpectomy, (1) we 
tracked the feature spaces of stiffness, activation and proliferation under fractionated radiotherapy.  
Sample stiffness defines the mechano-environment of the embedded cells that contributes to disease 
progression (Baker et al. 2010).  (2) Test cellular differentiation and overall contractility of 
myofibroblasts which would indicate reactive stroma (Desmouliere et al. 2004).  (3) Investigate cell 
proliferation rate via metabolic activity, which links aggressive and metastatic behaviors under 
radiotherapy (Martinez-Outschoorn et al. 2011).     
To our knowledge, no systematic investigation has observed cancer cell behavior for different 
radiation fractionation schedules in a residual disease model. The effect of radiotherapy in blocking the 
release of stimulatory factors during wound healing might lead to the development of optimal post-
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surgical fractionation schedules.  We hypothesize that 3D co-cultures are predicative models for this 
investigation.  Finally, in view of these postulated effects of radiotherapy on tumor-wound interactions, 
our ultimate goal is to deactivate cancer cells and their reactive stroma so the latter does not act as a 
promoter of the former.  It seems possible that a fractionated treatment which allows for a more 
complete recession of residual disease might be found using these methods.   
Post-operative radiotherapy has commonly been used for early stage breast cancer to treat 
residual disease. Due to differences in radiosensitivity and sublethal-damage repair rates between 
cancerous and noncancerous cells, dose fractionation parameters are important for maximizing the 
therapeutic ratio, where the limiting factor is the response of noncancerous tissues (patient tolerance).  
Fractionation schedules are selected to allow time for normal cells to repair radiation damage, while 
cancer cells are less efficient at repair (Hall 1994).  Failure of RT to control residual cancer-cell 
progression is still a major clinical challenge (Pinsky et al. 2007).  One method to overcome resistant 
residual disease of breast cancer is to change daily doses.  In fact the Standardization of Breast 
Radiotherapy Trails (START), have looked at late adverse effects and tumor control, which strengthen 
evidence in favor of alternative fractionation schemes, e.g, hypofractionated regimens, with potential 
for fewer adverse effects to normal breast tissues (Abram et al. 2008).  This study characterizes the 
fractionation schemes using stiffness, activation and proliferation to assess effectiveness in sterilizing 
residual disease in early stage breast cancer post-surgery. 
4.2 Materials and Methods 
4.2.1 Material 
Collagen type I stock solution (10 mg/ml, rat tail) were purchased from BD Biosciences (Bedford, 
MA, USA); 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) was obtained from Sigma 
(St. Louis, MO); Cell culture media consisted of Dulbecco’s Modified Eagles Essential Medium (DMEM, 
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Invitrogen, Carlsbad, CA) to which 10% fetal bovine serum (FBS, Sigma, St. Louis, MO, USA)  and 1% 
pen/strep (P/S, Sigma, St. Louis, MO, USA); Dimethylsulfoxide (DMSO) were purchased from ATCC 
(Rockville, MD, USA); 48 and 96-well cell culture clusters and other plastic disposables were purchased 
from Corning Inc. (Corning, NY). 
4.2.2 Cell Lines cultures 
The human mammary carcinoma cell lines MCF-7 and MRC-5 lung fibroblasts were obtained 
from the ATCC (Rockville, MD, USA). Both MCF-7 and MRC-5 cells were maintained in DMEM 
supplemented with 10% FBS and 1% P/S.  
3D Co-culture 
Type I collagen was used at a concentration of 10 mg/ml in accordance with our previous work 
(Qayyum & Insana 2012b). Collagen was chosen because it resembles the extracellular matrix milieu of 
invasive breast carcinoma better than other materials.  Collagen solutions were diluted and neutralized 
with medium and 1N sodium hydroxide to 2.0 mg/ml.  Cells were introduced to a particular sample at 
this time.  600 µl volumes of collagen solution were dispensed to a 48-well plate and incubated at 37°C 
as the collagen polymerized over 30 min.  After polymerization, 300 µl of complete DMEM was applied 
to the top of the gelled samples.  With or without cells, the total fluid volume added to each sample was 
600 µl so that matrix stiffness was not influence by medium volume.   
In co-cultures, 60,000 MCF-7 cells and 200,000 MRC-5 cells per 600 µl were used to mimic the 
residual disease in-vivo ratio of epithelial cells to fibroblasts in the human breast post-surgery. The same 
number of cells was seeded for each cell type cultured independently.  Cultures were maintained for 5 
days and the medium was changed every two to three days. 
4.2.3 Sample irradiation 
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Samples were irradiated by placing them in a 6 MV photon field generated by a linear 
accelerator (Varian Medical System, Palo Alto, CA, USA)(Qayyum & Insana 2012b).  Briefly, a uniform 
dose was delivered with the gantry set to 0 degrees and with a 100 cm source-to-axis distance.  An 8 x 8 
cm2 field size was selected to ensure cell culture samples were uniformly irradiated.  Dosimetric-quality 
solid water was placed above and below the well plates to provide proper build-up dose.  All samples 
were taken from the incubator and placed in a thermally isolating container for transportation to the 
clinic.  Once removed from the container, samples were exposed to IR at room temperature in a single 
dose and returned to the incubator within 30 minutes.   The standard clinical dose fraction for breast 
treatment of 180 cGy was delivered to samples at a rate of 400 cGy/min.  Other samples were exposed 
at the same dose rate but at a reduced fraction of 90 cGy or an accelerated fraction of 360 cGy.  All 
sample irradiations were delivered in 5 fractions, once each 24 hours over 5 consecutive days, so the 
total dose was 450, 900, or 1800 cGy. Dose delivery verification was conducted following clinical 
standards. 
4.2.4 MTT Assay 
In order to measure the metabolic activity at the irradiated cell monolayer, the 3-(4, 5-
dimethylthiazol-2-yl)-2, 5-diphenyltetrazolium bromide (MTT) assay was used. This is a sensitive, 
quantitative and reliable assay that measures the conversion of the yellow MTT substrate into a dark 
purple formazan salt by cellular dehydrogenase (Slater 1963).  The MTT assesses cell metabolism based 
on the ability of the mitochondrial succinate-tetrazolium reductase system to convert the yellow 
compound to a purple formazan dye.  Viable cells are able to reduce the water-soluble yellow colored 
MTT to a water-insoluble purple colored formazan product.  The amount of colored formazan product 
formed, determined spectrophotometrically after dissolving the formazan crystals in DMSO, is 
proportional to the metabolic activity of the test sample.  The general idea is that this metabolic activity 
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requires functional mitochondria.  The MTT assay is a common tool in radiobiology to assess metabolic 
activity (Rossi et al. 2000).   We have applied it to cell cultures in-vitro for the assessment of growth 
characteristics and cell survival.   
Cells were harvested from 75 cm2 culture flasks by trypsinization.  Cell were then resuspended in 
new medium (phenol free media), plated at different cell densities in 96-well culture plates and 
incubated at 37 °C in 5% CO2 for the time-period indicated in the legends of the figures. The cell medium 
was replaced every 2-3 day. Unless stated otherwise, rows 1, 3, and 5 contained cells for each condition 
studied and row 11 was used for controlled conditions (Media, MTT assay, and DMSO).  An example of a 
96 well plate is shown in Figure 16.  The cell monolayer is treated for 4 hours with MTT dissolved in PBS 
(concentration 5 mg/ml) at 37 ◦C and 5% CO2.  After incubation, the MTT solution is removed and 100 μl 
DMSO is added to each well of the 96-well plate to resolve the formazan crystals.  Plates were shaken 
for 10 min on a plate shaker to ensure adequate solubilization.  Assessment of metabolic activity was 
recorded as relative colorimetric changes measured at 570 nm. Samples were read in an Emax reader 
(Molecular Devices, Wokingham, UK) with software Softmax PRO version 4.3.  Control wells for 
absorbance readings contained no cells or medium but MTT solution was added as per experimental 
wells, and removed after incubation, and DMSO was then added.  All experiments were performed at 
least 3 times and the results were averaged.    
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Figure 16 Costar 96 well plate with cell densities ranging from 50,000 to 120,000 in rows 1,3, and 5.  MTT assay was added 
and the well was incubated for 4 hours.  After removal of MTT, DMSO was added to resolve the formazan crystals, picture is 
the at this step.  Increase in color intensity from top left to top right is due to increase cell number.  Controls material in row 
11. 
 
4.2.4.1 Calculation of Absorbance rate: 
Once a linear range was found from the standard curves, we chose the 20,000 cell concentration 
to observe for a 5 day period since in fell within linear range of 10,000 to 30,000 cells.   The absorbance 
values at day 0, 3 and 5 were plotted and the slope taken to derive a rate of absorbance changes over 
the period of time (Figure 17).  What is plotted in figure 16 for control and the 90cGy fraction dose 
conditions of the absorbance value at day 0 where 20,000 cells/µl initially and measured.  Then the 
same density was tracked over 3 days and measured then 5 days and measured.    A linear response was 
found over the 5 day period.  The slope of the lines is what we report as the change rate of absorbance 
(metabolic activity) over the 5 days.   
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Figure 17 The MTT assay done on the well plate containing an initial value of 20,000 cells/µl observed at day 0, 3 and 5 days.  
 
4.2.5 Immunofluorescence staining (IF) 
MRC-5 and MCF-7 cells were mixed at a ratio of 3:1 in collagen type I gel at a final collagen 
concentration of 2 mg/ml. Collagen gel co-culture was maintained in DMEM containing 10% FBS and 1% 
P/S at 37 °C in a humidified atmosphere containing 5% CO2.  To quantify the cell growth in collagen gel 
following mechanical testing, collagen samples were fixed as follows.  Samples were washed with 
Phosphate-Buffered Saline (PBS, Lonza, Wackersville, MD, USA) before being fixed with 4% 
paraformaldehyde at 4°C overnight.  Samples were then washed and permeabilized in 0.02% Triton X-
100 in PBS for 15 mins followed by 5% non-fat milk blocking for 2 hours. Gels were then incubated with 
primary antibody, consisting of Bovine Serum Albumin (BSA, Sigma), PBS and Tween 20 (T, Sigma), 
(1:100 in 1% BSA/PBS/T) overnight at 4°C and secondary antibody (1:200 in 1% BSA/PBS/T) at room 
temperature for 2 hours. Cell nuclei were stained with TO-PRO 3 (1:1000 in PBS) for 20 mins.  Sections 
were mounted between two glass coverslips with anti-photobleaching reagent.  
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4.2.6 Confocal microscopy  
Immunofluorescence-stained samples were examined with a Leica SP2 laser scanning confocal 
microscope (Leica, Heidelberg, Germany) with Hg lamp and helium/neon laser and the associated 
software (Leica Confocal Software Version 2.00).  A 488 nm excitation wavelength was applied for 
Fluorescein isothiocyanate (FITC) mapping, and a 633 nm excitation wavelength was used to find nuclei 
via TO-PRO 3 mapping.  For each sample, a 20X objective captured a series of images along the z-
coordinate (sample depth) at 3-5 μm increments.  For confocal microscopy, an imaging system was 
employed (Microradiance; Bio-Rad, Philadelphia, PA, USA) consisting of a 25-Mw argon ion laser 
emitting at 488 and 514 nm and a 1-Mw green helium–neon laser emitting at 546 nm attached to a BX-
50 microscope (Olympus Imaging America, Inc., Center Valley, PA, USA).   
4.2.7 Automated area quantification and cell counting 
MCF-7 cells seemed to aggregate in cell clusters within 3D microenvironments.  Their 
morphologies were very different from MRC-5 cells; MCF-7 presented relatively rounded and less spread 
morphology and fibroblast are distinct in having a clearly recognized nucleus with long-tail cell bodies 
expressing α-SMA.  These techniques were used to provide a quantification of proliferative rates for 
each cell type. 
Cell number and area was counted using automated segmentation software. To differentiate 
MRC-5 and MCF-7 cells in the co-culture sample, both TO-PRO3 red and FITC green fluorescent (GF) 
images were taken and merged. MRC-5 cells were distinguished from MCF-7 cells by virtue of their 
elongated shape and α-SMA expression. In the MCF-7 cell growth assay, a nucleus size exclusion 
strategy was applied during the cell counting procedure.  MRC-5 cells displayed a more elongated nuclei 
staining than MCF-7 cells and MCF-7 cells are more circular, thus they could be differentiated during the 
counting process. Therefore, we collected the red circular images and then analyzed the MCF-7 cell 
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number and area. We calibrated this counting method with a hand counting method to validate the 
software.  Both methods gave consistent MRC-5 cell number, however the software had a systematic 
under counting of the MCF-7 cells.  So, the values given are accurate within a measured bias.  A detailed 
description can be found in Appendix A, section 2.   
4.2.8 Mechanical testing 
The experimental protocol is the same as that used in our previous study (Qayyum & Insana 
2012b).  In brief samples were mechanically tested using a TA.XT Plus Texture Analyzer System with a 1 
kg load cell (Texture Technologies Corp., Scarsdale, NY, USA) and a compressive indentation procedure 
with 1 hour following delivery of IR.  The fluid medium was removed from the top of the sample before 
testing with a 5-mm-diameter spherical indenter.  The indenter was pressed into the sample surface at 
low velocity, 10-1 mm/min and to a depth of 2.5 mm.  Force (F) and displacement (d) were recorded by 
the instrument to estimate sample stiffness.    
4.2.9 Statistical analysis 
Analysis of variance (ANOVA) was performed using R software to determine the significance of 
differences at a  = 0.05 level.  Observed differences among mean sample groups were evaluated with 
post-hoc analysis, including Tukey HSD.   This method was similar to one done earlier in section 3.2.9.   
4.3 Results 
4.3.1 Cell viability and proliferation 
Calibration curves 
The 3 cell types (MCF-7, MRC-5 and CAFs) underwent the MTT assay to measure metabolic 
activity.   All three cell types were plated into 96 well plates in serial dilutions ranging from 5,000 – 
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120,000 cells/µl.  To calibrate our system, we first ran a standard curve for each cell type.  This was done 
by plating the full range of cell densities in a 96 well plate and allowing time for attachment, but not 
propagation.  We then added the MTT assay to acquire the exact absorbance level per each well.  The 
assay was allowed to incubate for 4 hours, before the medium was removed and the dye was dissolved 
with 100 µl of DMSO. The optical density was measured at 570 nm using a photospectrometer.  The data 
in Fig. 18 indicates a logistic curve relationship between absorbance signal and cell number, and there is 
a range in which this relationship is linear.  For each cell type the linear range was determined from 
Figure 18 and found to be from 10,000 to 30,000 cells.  A logistic curve behavior was observed for the 
following reason; at the lower ranges there is less direct cell contact and less paracrine signaling leading 
to lower metabolic activity and thus lower absorbance (Range < 5000 cells).  At the linear range, MTT 
absorbance increases linearly with cell density.  Cells are close enough to each other for paracrine 
signaling to occur and are more metabolic activity (range 10,000 to 30,000 cells).  Cells make contact 
with other cells through the cell surface by means of specific glycolipids and glycoproteins embedded in 
the membrane.  This signaling mechanism is important in cell recognition.  In addition to these contact 
interactions cells have to communicate with each other to relate the need for metabolites, fuel 
molecules, growth and cell division.  These interactions are based on the release of chemical substances 
which travel to target cells.  At the target cell, these messenger molecules attach themselves via a highly 
specific interaction to membrane bound receptors.  This in turn leads to the activation of certain 
enzymes inside the cell initiating a particular cellular response.   
If there are too many cells, there are two potential problems.  The first is that an unwanted 
variable of media depletion is added to the experiment. The cells quickly use up the vital nutrients in the 
media and their growth rate decreases. Second is the limitation of the equipment, where absorption 
measurements are saturated above a reading of 4 so that we cannot distinguish between all numbers 
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greater than 50,000 cells/µl.  Fibroblast and CAFs were limited by their cell density and size within the 
well to maximum of 60,000 cells/well.   
 
Figure 18  Standard curves, for cells plated in a serial dilution ranging from 5,000 to 120,000 cells/µl were incubated for 4 
hours with MTT as described in Materials and Methods. At the end of the MTT-incubation period, the formazan crystals were 
dissolved in DMSO. During the experiment the formazan/dimethyl sulphoxide solution was kept in the dark at room 
temperature.  The data indicate a relationship between absorbance signal and cell number, and there is a range in which this 
relationship is linear. 
 
4.3.2 Absorbance as a measure of cell proliferation 
Provided that the sample measurements are within the linear part of the absorbance curve, cell 
number can be determined by observing the absorbance of a test sample after the desired time period.  
We established a relationship between absorbance seen from the MTT assay over a 5 day period and 
cell counting from confocal imaging of IF stained samples as estimated from the area calculation of MCF-
7 cells over 5 days.  From the linear curve of absorbance versus cell area cluster (Fig. 19) we can 
establish that absorbance is an indication of cell proliferation and that the metabolic activity per cell is 
not changing significantly.      
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Figure 19 Absorbance from MTT assay for an initial plating density of 20,000 cells/µl at day 0, 3, and 5 days for MCF-7 cells 
versus the area over 0, 3 and 5 days from IF staining.  INSET: Automated output of the area for samples at 72 and 120 hours.  
Error bars indicate one standard error of the mean (SEM). 
 
The interpretation of figure 18 for the MCF-7 cells would indicate the proliferative nature of the cells.  As 
a function of time from days 0, 3 and 5 days the cell number is increasing along with the metabolic 
activity.  The R2 value of the linear fit is 0.9999.  This suggests that absorbance and cluster area are 
linearly related.  The increase in absorbance signal in the MTT assay is a result of the proliferation of the 
MCF-7 within the well plates.  If the conversion of the MTT assay, which indicates metabolism, per cell is 
constant, then the increase in cluster area should track the increase in absorbance.  Thus tracking 
metabolic activity would indicate proliferation since cell cluster area is going up.   
4.3.3 Response for all the cell types under calibration curves 
Even when calibration curves of the number of cells counted versus absorbance values obtained 
with the MTT assay are derived from the linear portion of standard curve, the slope of the calibration 
curves are different for different cell lines (Fig. 18). This suggests different capacities of cells to produce 
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formazan, possibly as a result of different morphology and growth characteristics of these various cell 
lines.  The steeper the slope, i. e., the higher the amount of formazan produced per cell, the higher the 
absorbance value up to which the relationship between cells counted and absorbance is linear.  Growth 
rate and morphology of cells in culture also seem to play a role.  For the CAFs there seems to be higher 
rate in metabolic activity than MRC-5 fibroblast at the same number of cells plated.  
4.3.4 Metabolic activity and Fractionation 
The results of our investigation on the metabolic activity of the control samples show 
proliferation of cells, and unlike the IF staining the MTT assay can distinguish between viable and dead 
cells.    MCF-7 cells seem to be the most sensitive to radiation, where the higher dose fractions induced 
the greater reduction in metabolic activity.  As shown in Figure 20a, the surviving fraction remained 
constantly lower than the untreated controls, indicating that MCF-7 cells are highly sensitive to radiation 
(overall p <0.05).  Based on this result, the next studies were conducted by examining MRC-5 fibroblasts 
under normal conditions and CAFs by inducing differentiation with TGF-β1.  Results are expressed as the 
change in rate of metabolic activity over 5 days (Fig. 20 a,b,c).  Normal MRC-5 fibroblasts are more 
radioresistant than MCF-7 cells.  It is significant to note that CAFs are the most radioresistant of the 
three cell types (Fig. 20c).   
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Figure 20 Metabolic activity of MCF-7, MRC-5 and CAFs.  Error bars indicate one standard error of the mean (SEM). *indicates 
statistical significance at the p < 0.05 level. Significance was taken of adjacent values as well as protocols.  Details of activity 
calculations can be found in Appendix C under calculation of absorbance rate section. 
(a) 
(b) 
(c) 
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From figure 20, we see that the absorbance, determined by the formazan concentration, normally 
decreases with increasing radiation dose as was reported previously (Bromley et al. 2006).   If decisions 
are based on cancer cells alone, plot (a) would be used, using 180 cGy fractions would save the patient 
some extra risk.  The microenvironment also consists of CAFs, from plot (c) it is apparent that a standard 
fraction gives a small response; however if a higher dose is used, it would cause higher cancer cell death 
and if tolerated by the patient a fourfold increase in CAFs reduction would be achieved.  This method 
would help in the clinical decision making process.  This is possible as seen in studies, such as the START 
trails referenced earlier which favor use of hypofractionated (i.e., larger fraction size) breast irradiation 
because it provides excellent long-term local control and limited late morbidity as well as benefits of 
convenience and cost.       
4.3.5 Stromal Fibroblasts Stimulate Breast Carcinoma Cell Growth  
To characterize the behavior of collagen co-culture in a 3D environment, MCF-7 cells were 
embedded in collagen gels, with or without the addition of MRC-5 fibroblasts.  Based on preliminary 
studies, a 3:1 ratio was chosen of MRC-5 and MCF-7 cells, respectively, to be used throughout the 
investigation.  Since the MTT assay, as performed in our study, provides information on total cells 
viability (overall metabolic activity) and not the spatial orientation of cells or activity, we detected the 
area of MCF-7 cells by the IF staining, in which MCF-7 and MRC-5 fibroblast cells can be easily identified, 
counted and measured.  As MCF-7 cells proliferate they cluster which makes it difficult to count, so an 
initial quantitative assessment of cell growth was performed by measuring the total area occupied by 
MCF-7 cell clusters.  An initial assessment of the MCF-7 alone indicated an increase in cluster area over 
the 5 days.   
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Figure 21 MCF-7 Cluster area over a 5 day period under control and IR fractionations.  The presence of MRC-5 induced MCF-7 
cell growth, resulting in large, irregular, and partially branched epithelial cell clusters. 
 
In contrast, the presence of MRC-5 fibroblast induced a significantly greater MCF-7 cell growth, resulting 
in larger and more abundant MCF-7 cell clusters (Fig. 22). MCF-7 cells were identified and distinguished 
from MRC-5 by morphological differences as stated earlier.  MCF-7 cell clusters composed of one cell to 
more than a hundred cells were included in the analysis.  A quantitative assessment of epithelial cell 
numbers revealed that the presence of MRC-5 fibroblasts caused a highly significant growth stimulation 
of the MCF-7 cells from day 3 onward.  To determine whether the software area is an acceptable 
surrogate measure of cell number, MCF-7 nuclei were counted manually in randomly selected clusters 
and the number of nuclei was correlated with the absolute software area. Analysis demonstrated that 
cell numbers were consistently under counted by the automated cell counting software method (A 
detailed description of this process can be seen in Appendix A). 
 
 67 
 
4.3.6 Co-culture response to IR 
Co-culture samples were exposed to 5 sequential daily fractions of either 90, 180 and 360 
cGy/fraction, for a total dose of 450, 900 and 1800 cGy.  The number of cells, as indicated by cluster 
area, that result as a consequence of these radiation treatments during treatment on day 5 are 
illustrated in Fig. 21. Each  fraction scheme of radiation were sufficient to inhibit MCF-7 cells growth 
when cultured alone, though the higher fraction of 360 cGy induced the greatest reduction in MCF-7 
cluster area. However, in the co-cultures exposed to the same amount of radiation, the average 
numbers of MCF-7 area were larger, though not a significant difference at p > 0.05.  With the high 
fraction dose of 360 cGy, the damage was much more pronounced than the lower fraction doses; there 
was a significant difference (p < 0.05) in MCF-7 area (Fig. 21).  This further demonstrated stromal 
component, such as CAFs impact the response of MCF-7 cells to radiation. 
4.3.7 Fibroblast ability to contract after IR 
We went on to investigate the functional status of irradiated cells, with particular emphasis on 
stiffness, which have been shown to influence tumor invasiveness and angiogenesis (Baker et al. 2010). 
If we just have fibroblasts we get stiffness when incorporated into collagen.  Now if we add growth 
factor, which we know from our previous experience, will transform the cells and produce an increase in 
stiffness more than double the control because the fibroblast are being activated (Figure 22).  Now if we 
create co-culture, we are not adding growth factors but we are aware cancer cells also produce growth 
factors.  So, we can see almost the same response as that with growth factor.  By stimulating the co-
culture with growth factor, we see an added impact on the stiffness.  The stiffness values all seem to 
bunch around 2.5 to 3 N/m stiffness range.  We attribute this is to the active contraction that the growth 
factor is causing the fibroblast cells to contract which is making our sample stiff.  Once we irradiate 
these samples at the early stage where cell arresting is leading to a decrease in stiffness, however with 
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increasing the dose we are causing crosslinking of the matrix leading to stiffness.  We must keep in mind 
that radiation has a passive effect – which causes crosslinking as seen in figure 10.  This reduction, we 
think is the deactivating of the cells, where fibroblasts are either actively contracting or not.  All fraction 
sizes caused a decrease in stiffness.  However a significant difference in stiffness was found between the 
lower fractions of 90cGy and 180cGy to the 360 cGy fraction size, which we attribute to the passive 
impact of radiation on the collagen matrix leading to crosslinking.  Overall, these results indicate that 
while CAFs appear to survive high radiation doses, however their contraction capacity is considerably 
compromised. 
 
Figure 22 Measurements of sample stiffness (a), total cell number per sample (b), and cell activation ratio (c) for collagen gel 
samples (Groups 3 and 4) formed with fibroblast cells and without TFG-β1.  Group 4 samples are given three daily IR fractions 
at the three times indicated. Each bar in the stiffness results is taken from measurements on N=6 samples (mean ± 1 SE).  Cell 
numbers (b) and activation ratios (c) are for N=4 samples. No radiation was given to the control samples.  * indicates 
statistical significance at the p < 0.05 level.   INSET: IHC-stained confocal fluorescent images for (i) a non-irradiated sample 
and (ii) a sample irradiated with 2 fractions of 180 cGy.  Both samples were imaged after 48 hours. 
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Our data shows that radiation doses exert advantageous inhibitory effects on the proliferative, 
contracting capacity on CAFs, thus hindering some of their pro-malignant properties. 
4.3.8 Post treatment evaluation of cancer cells 
The clinical bench mark of treatment efficiency is post treatment survival of five years.  Even 
though, we did not look at the bench mark, we extrapolated by doubling the time after exposure of 
radiation.  This will be an indication as to what occurs when we turn off the radiation and observe the 
effects.  The 90cGy fraction size was not evaluated because it is not clinically relevant for early state 
breast cancer; just the standard of 180cGy and doubling of the standard (360cGy) was used.  The cancer 
cell cluster area post treatment is depicted in Figure 23, which represents the MCF-7 cluster area.  
Without any radiation, the MCF-7 cell cluster area increased and kept growing.  However, samples after 
radiation showed a decrease in the MCF-7 area.  Five days post-treatment the cells started decreasing in 
size due to delayed cell death response.  Samples which had growth factor TGF-β1 seemed to have a 
larger MCF-7 cluster area.  Radiation-induced apoptosis can be mediated by either of two pathways: 
intrinsic or extrinsic. Activation of the cascade of caspases is common to both pathways. Targets for 
cleavage by caspases include proteins involved in DNA repair, DNA replication, cytoskeleton regulation, 
and the nuclease that causes DNA fragmentation.   
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Figure 23 Cluster area post treatment.  Without any radiation, the MCF-7 cell cluster area increased and kept growing.  
However, samples after radiation showed a decrease in the MCF-7 area.  Five days post-treatment the cells started 
decreasing in size due to delayed cell death response.   
 
4.3.9 Reactive Stroma response of stiffness 
 For the non-treatment condition, we observed that the parameter of stiffness does not continue 
to increase. Co-culture past day seven shows that stiffness starts to decrease due to cancer cell cluster 
size increasing faster than fibroblasts’ growth and contraction (Fig. 24).  This may be due to the 
increased presence of MCF-7 extracting nutrition present in the culture leading to the diminished role of 
MRC-5 fibroblast.  In regards to post-treatment, stiffness of the co-culture was reduced for all 
fractionation schemes. Radiation damage is largely manifested by the loss of cellular reproductive 
integrity.  Some cells undergo apoptosis (triggered death), which would not show morphologic evidence 
of radiation damage until they attempt to divide.  Irradiation causes reduction of stiffness by 
deactivating the cells, causing fibroblasts to be active or inactive.  For the slight increase in stiffness that 
was observed for the samples with growth factor, it was perhaps due to growth factors leading to 
contraction of residual fibroblasts post-treatment.      
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Figure 24 Stiffness response post treatment.  Co-culture past day 7 days stiffness starts to decrease due to cancer cell cluster 
size increase.  Irradiation causes reduction of stiffness by deactivating the cells (Fibroblast – on or off).  For irradiated 
samples with growth factor leads to contraction of residual fibroblasts.      
 
4.4 Discussion 
We see our investigation as a new approach between radiobiology and radiotherapy.  In the 
past radiobiology was looking at specific diseases or cell types not under natural conditions.  We wanted 
to generalize these conditions and developed a 3D co-culture model to evaluate the dose fractionation 
schemes relevant to clinical practices.   
Clinical studies look at recurrence rate, patient susceptibility and 5 year survival rates. However, 
we are looking at an abstract view of component interactions coupled with responses to radiation 
therapy, the signaling between stromal cell types and cancer cells in their environment.   
The focus of therapy is the cancer cells, but nonetheless in our study we found the 
microenvironment to also be important in that if not suppressed it may harbor any residual disease, 
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reigniting tumor growth.  So, the feature space of fibroblast activation, stiffness and proliferation are 
important parameters within the matrix that derive fibroblast conversion and stiffness responses.   
Myofibroblasts or CAFs have been found in a variety of normal tissues and various pathological 
situations, including wound-healing, fibromatosis, and stromal reaction to epithelial tumors (Morishima 
et al. 2001).  We found fractionation studies with MRC-5 fibroblasts and CAFs indicate that higher 
fraction doses may be more effective early on in preventing cancer harboring environments. Higher 
fraction schemes inhibit contractility in CAFs and prevent differentiation in fibroblasts, thereby 
metabolically uncoupling tumor cells from their surrounding stroma. 
The conclusion that MRC-5 fibroblasts definitively modulated the response of MCF-7 cells to 
radiation relies on two main considerations.  First, using the MTT assay on different cell types, CAFs 
were found to be most resistant to radiation in terms of metabolic activity i.e., for all fractionation 
schemes on both days 3 and 5 (Fig. 19).  The observation that CAFs were resistant and MCF-7 cells were 
sensitive, suggesting that the target of interest should also include the CAFs and not only MCF-7 cells.  
These observations bring forward a new concept that tumor cells and their reactive stroma should not 
be merely seen as a morphologic domain but also as a functional domain with a genuine metabolic 
cooperation between the cancer cells and newly formed CAFs.  Second, by the cell counting and area 
clusters performed on collagen gels, the number and size of MCF-7 clusters from the gels containing 
mixed MCF-7 and MRC-5 fibroblast cells were significantly increased compared with the number and 
size of the clusters from the gels containing MCF-7 cells alone (Fig. 20).  Taken together, these results 
suggest that fibroblasts and cancer cells in co-culture become metabolically coupled, resulting in the 
development of a “symbiotic” relationship.  As seen in figure 20 the area of MCF-7 increases with co-
culture than in cell culture alone.   
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Putting this information together, the metabolic activity, as indicated and explained in Fig. 19 
and based upon IF staining directs the importance of biochemical fluxes within the microenvironment 
consisting of tumor and stromal components. The distinctly different but complementary metabolic 
function of MCF-7 cells and CAFs shows a complex spatial organization compatible with synergistic 
support to each other.  Indeed, many investigators stressed the unique characteristics of CAFs (Olumi et 
al. 1999; Desmouliere et al. 2004). These are, in essence (together with the ECM), the main component 
of stromatogenesis (i.e., the process of new stroma formation occurring concurrently with tumor cell 
invasion and angiogenesis). The newly formed stroma not only provides tumor cells with a substrate 
suitable for tumor cell growth and proliferation but also offers them metabolic support essential for 
cancer cell survival. These findings direct attention to the stromal components along with the tumor, 
which might give rise to an improved therapeutic ratio.   
Tumors are characterized by ECM remodeling and stiffening (Levental et al. 2009).  Our 
experimental results both improve our basic understanding of mechanobiology of the 
microenvironment, metabolic activity, as well as identify relevant therapeutic responses.  Many 
investigators have found breast cancer tissue to be as sensitive to fraction size as dose-limiting healthy 
tissues (Owen et al. 2006; Abram et al. 2008; Prosnitz et al. 2009).  Fibroblasts, CAFs and the factors they 
produce are important targets for RT and prove to be useful prognostic markers.  These findings confirm 
that radiotherapy schedules can be evaluated through metabolic activity, stiffness and differentiation 
changes.   
Expanding beyond cancer cells by including the microenvironment and looking at interactions 
provides new insights into long term sustainability of tumor regeneration.   Evaluation of alternative 
fractionation techniques i.e. Hypofractionation may result in a useful alternative to standard breast 
cancer RT.  There is value in a technique which reduces the treatment time while maintaining cosmetic 
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and functional control, if by adjusting fraction size from standard protocols does not adversely affect 
stiffness or differentiation changes.   
This proposed technique provides a useful tool to systematically optimize radiotherapy and 
sheds important insight into the complex problem of dose-time fractionation.  The presented feature 
spaces outlined earlier allow us a better understanding of the influence of various biological parameters 
on RT treatment of cancer.  This may provide a practical tool to obtain the optimal total dose, overall 
treatment time, fraction sizes, and intervals for each disease site.  In summary, though clinical decisions 
cannot be derived from cell culture studies, nonetheless targeting CAFs as a therapeutic strategy against 
cancer is an intriguing concept that requires further research. 
The development of Intensity Modulated Radiation Therapy (IMRT) (Fig. 25), results in greatly 
improved dose distributions, with more limited doses to normal tissues for comparable tumor doses. 
One of the most important advances has been in IMRT as a type of 3-D conformal radiotherapy which 
supports complex beam delivery schemes. IMRT produces high dose conformation to target with normal 
tissue avoidance and subsequent potential benefit to both reduced normal tissue toxicity and dose 
escalation to tumor to increase local control. The beam can be moved while the patient is fixed in one 
position. The patient does not have to be in close contact with beam structure which makes it easier to 
implement complex beam movements together with simple and comfortable patient positions.  The 
IMRT computer planning implements an inverse sequence of the normal planning process used in 
conventional radiation therapy. The conventional approach to radiation is to try to develop an 
appropriate treatment plan for the tumor by trial and error simulations on a computer.  Sophisticated 
IMRT computer technology is used to determine the best way to achieve this result, thus shaping the 
dose cloud to the tumor. This suggests the attractive possibility of increasing the dose per fraction.  
These techniques can greatly reduce the duration and cost of therapy and may minimize the effects of 
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accelerated tumor repopulation triggered by RT itself.  It is therefore appropriate and safe to embark on 
such non-standard fractionation clinical practices. 
 
 
Figure 25 Boost irradiation (IMRT) at the site of tumorectomy, 1600 cGy over 8 fractions. Rationale of this strategy is most 
local recurrences appear close to the tumorectomy cavity and spare the patient late radiation morbidity.  Courtesy of 
Provena United Samaritans. 
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CHAPTER 5 
CONCLUDING REMARKS 
 
5.1 Conclusions 
The overall objective of this research is to develop a model for 3D cell culture in order to better 
understand the effects of fractionation in radiation therapy for breast cancer.  My specific aims are as 
follows. (1) To systematically map 3D stromal cell culture responses to fractionated radiotherapy (the 
effects of fractionation schemes on collagen matrix stiffness and fibroblast activation were studied using 
this culture model). (2) To establish a 3D cell co-culture model by incorporating more breast tissue 
components such as a cancerous mammary cell line into a fibroblast-collagen gel to mimic more natural 
signaling conditions.  The purpose of this was to produce co-cultures that will be used to deliver 
fractionated courses of radiation prescriptions that enable measurements of the cellular 
microenvironment. (3) In addition, I exposed a co-culture model to altered fractionation schemes to 
process optimized dose per fraction for eradication of residual disease.  We tracked a feature space that 
includes collagen matrix stiffness, fibroblast activation and epithelial cell proliferation.  The parameters 
may eventually provide a metric for clinical decision-making.  Acquiring the data stated in this thesis has 
improved our understanding of IR fractionation on a subset model of residual diseases.  With more 
research in this data we may be able, as I had intended, to optimize clinical decision making. However, 
at the conclusion of this thesis project such clinical decisions cannot be definitive.     
I have reached my short term goals but in order to reach my long term goal I have to extend this 
study to develop animal models.  This will increase the level of complexity and realism of this research at 
the cost of some clinical control being lost. However, using my understanding of cell culture as 
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developed in this research, I would be equipped to assemble a theory on the data produced in the more 
advance models.  Once data from an animal model is analyzed, we can apply that data to formulate in-
vivo patient trials. Thus, data collected from previous models can be used to study and evaluate data 
gathered in patient trials.  
Currently patients at treatment centers are receiving treatments based on modern techniques 
that better shape the radiation dose distribution to the target volume (e.g., IMRT based on computed 
tomography of the breast and surrounding normal tissues). As a physicist at Provena Covenent Hospital, 
I noticed that treating patients with breast cancer using these modern techniques makes it possible to 
deliver an effective dose of radiation to the tumor volume with reduced toxicity to surrounding tissue. 
As such we are able to deliver higher doses of radiation with little or no increase in toxicity. This 
observation was based on an evaluation of patients receiving an IMRT boost after their conformal 
treatment. These patients did not have an adverse reaction to the elevated dose directed at the tumor 
region.  These methods have been fully adopted at this cancer institute and it has become apparent that 
the delivery of higher doses by conformal radiotherapy and IMRT has led to a significant improvement in 
the treatment of patients with breast cancer. These clinical practices significantly increase the rate of 
local tumor control without an increase in treatment-related side effects.     
However, it cannot be conclusively stated that achieving significant improvement in the 
therapeutic ratio depends only on advances in the technology of radiation delivery. It is important to 
understand the mechanisms that govern the sensitivity of cancer cells and normal tissues to radiation. 
This will make it possible to improve the therapeutic ratio and, hence, the probability of obtaining 
permanent tumor control without the result of severe injury to normal tissues. 
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Further research using animal models and clinical trials are needed to test the safety and efficacy of 
cancer treatments that target the cancer cell and the wound healing pathway utilized by the cancer cell 
to proliferate and metastasize. 
5.2 Future Outlook 
This study is an initial step in my career plans to study stromal modulation of epithelial tumors. 
It is also my objective to integrate basic science experiments and engineering tools into clinical practice. 
As such, I plan to translate the knowledge acquired from the laboratory experiments conducted in 
pursuit of this thesis into clinical standards.  In a larger context, the elucidation of a microenvironment 
controlled cancer behavior and its control mechanisms can provide major guiding principles in the 
search for biomarkers of improved therapeutic ratios.  
Imaging tools 
This data can potentially be used to develop a device that is able to diagnose the 
microenvironment with the parameters of stiffness, activation and proliferation.  
Physical forces coupled with bimolecular signals cause certain cell behaviors as demonstrated by 
our cultures, such as the differentiation leading to contraction and thus stiffness of matrix.  Within our 
culture, cancer cell proliferation occurs and irradiation leads to crosslinking of the matrix, stromal cell 
activation and deactivation.   How can we turn this into a diagnostic tool, which may be able to look at 
stromal cell activation? Any molecular imaging tool that can lock onto a fibroblast when it is converting 
is an indicator of stromal cell activity.  There might not be a method currently available; however, we 
have the ability to measure stiffness as a parameter for stromal activation.  We can measure stiffness 
locally on the order of resolution of an imaging system, such as ultrasound which is on the order of a 
millimeter.  Though, stiffness is an elastic modulus and a static value, which has a low specificity; 
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however the viscous component which is the dynamic parameter may be more telling.  So, it may not be 
enough to only look at stiffness but also evaluate the dynamic component of viscous response of the 
microenvironment.  So, there are methods to look at the static response as I have done, but to study the 
viscous dynamics there is shear wave imaging.  Shear wave imaging is one of the dynamic methods in 
quantitatively evaluating the elastic parameters of the tissue. It utilizes the phase velocity and 
attenuation coefficient information of the propagated shear waves in tissue to reconstruct mechanical 
properties.  This might be an important application of the stiffness mapping to give us an assessment of 
the microenvironment surrounding a cancer cell post-surgery.  For example, looking at the relationship 
between activation and stiffness (figure 14) we can be able to determine the nature of the stromal 
environment.   
The Role of Molecular Imaging in Evaluating Tumor Response to Targeted Radiotherapy 
Positron emission tomography (PET) has become one of the most important molecular imaging 
modalities in clinical oncology. This success is primarily based on the ability of PET to measure and 
visualize the increased glucose metabolism of cancer tissue by using the radiolabeled glucose analogue 
18F-fluorodeoxyglucose (FDG). However, our findings have important implications for re-interpreting 
the PET scans of human tumors using Fluoro-2-deoxy-D-glucose (F-2-DG), as glucose uptake was 
previously thought to be solely the domain of cancer cells. Instead, here we see that CAFs show 
increased metabolic activity, just as cancer cells do under identical culture conditions. Thus, increased 
PET glucose avidity may actually be a surrogate marker for a reactive stroma, allowing the rapid 
detection of a lethal reactive microenvironment. 
Staging of cancer patients has evolved as the most important clinical application by providing an 
accurate assessment of the localization, extent and spread of disease. FDG-PET can assess tissue glucose 
utilization with high reproducibility (Figure 26). Following therapy, the decrease of tumor glucose 
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utilization correlates with the reduction of viable tumor cells, however it may be more telling of the 
reactive stroma that is a result of post treatment. Thus, FDG-PET may allow for the assessment of 
therapy response by determining the viability of residual masses after completion of treatment.  
 
Figure 26 Axial PET/CT slice of a patient with an inflammatory carcinoma of the right breast showing increased activity 
diffusely through the breast and involvement of both axillary level I and internal mammary lymph nodes. (Courtesy of 
Provena United Samaritans) 
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APPENDIX A 
AUTOMATED CELL COUNTING 
 
(1) MRC-5 Fibroblast only 
Phenotypically, activated fibroblasts are characterized as expressing large amounts of α-Smooth 
Muscle Actin (α-SMA).  To observe differentiation of fibroblast cell, Immunofluorescence (IF) staining 
was done.  Confocal imaging resulted in number of images that required α-SMA-stained cells and nuclei 
counting to quantify activation ratios.  Here, we developed an automated segmentation method to 
recognize and count two different types of staining from a confocal image.  The percentage of cells 
expressing α -SM Actin was determined by a computerized Count Activated Cells Thresholding image 
analysis program, developed by our lab.  It was used to maintain a constant threshold for determining 
positive differentiation of cells, represented in figure 27.  In order to count the total cell number and 
activated cell number, we detected red fluorescence regions (nuclei, representing total cell number) and 
green fluorescence regions (α-SMA, representing activated cell number) in the images from confocal 
microscope.  The activation ratio was defined by    
( )N u m b e r o f A c tiv a te d F ib r o b la s ts N u m b e r o f G F R N
A c tiv a tio n R a tio
T o ta l N u m b e r o f F ib r o b la s ts N u m b e r o f R N
  . (1) 
Where Number of Green fluorescence represents α-SMA and the denominator indicates the total 
number of red nuclei and intersection of green cell bodies. Since both red and green fluorescence 
regions in the images are brighter than background, but the level and pattern of noise vary from image 
to image. To reject image noise while identifying valid fluorescent objects to be counted, 2-stage 
Percentile (P-tile) thresholding is applied to the images (Doyle 1962). The P-tile threshold value was set 
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to be 50 percent greater than background noise.  The fluorescence of interest was the area with values 
above the P-tile threshold. The fluorescence we are interested in is assumed to be present in the area 
above the P-tile threshold value. To eliminate the artifacts, we restrict the candidate objects by their 
intensity and size. For each candidate object, we collect pixels (B) surrounding the object, and the 
intensity threshold value is determined as AVG(B) + STD(B) where AVG(•) and STD(•) represent average 
and standard deviation of •. The size threshold value is computed as 0.5 * Smedian where Smedian is the 
median size of all candidate objects. Have detected both red and green fluorescence, we count the 
number of total and activated cells. The total number of cells in an image is the total number of red 
fluorescence objects, and the activated cell is the red fluorescence object where more than 30% of the 
pixels in the object are also designated to have green fluorescence. 
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Figure 27 Automated cell counting and cell activation ratio calculation. (a) Confocal fluorescence microscopy image (20×). α-
SMA is shown in green and nuclei are in red. Green cell bodies that meet the threshold criteria are counted as activated. (b)-
(e) show results of the automated segmentation method applied to a green fluorescence image. The same method was used 
for red fluorescence images (not shown here). (b) Input image of green fluorescence. (c) Global P-tile thresholding. (d) Local 
P-tile thresholding. (e) Intensity and size restriction. (f) Computer generated image for automated cell counting. α-SMA is 
shown in green; nuclei are in red for cells with α-SMA and in blue for cells without α-SMA. (Acknowlege: R. Bharagava & J.T. 
Kwak) 
 
(2) Co-culture study – Automated Area quantification and cell counting 
We detect red fluorescence regions (representing nuclei of MCF-7 and MRC-5 cells) and green 
fluorescence regions (representing activated MRC-5 cells) in the images of confocal microscopy. Both 
red and green fluorescence regions in the images are brighter than background, but the characteristics 
of the fluorescence are different and the level and patterns of noise vary from images to images. To 
handle noise and better represent the candidate fluorescence objects, we adopt the concept of scale-
space theory. Fluorescence should exist as meaning objects over certain ranges of scale and be robust to 
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the scale variation within the ranges, but not noise. Accordingly, we generate a number of Gaussian 
smoothed images with varying sizes (                  ) and add them to the original image. 
Nuclei and green fluorescence of MCF-7 are relatively round or elliptical and MRC-5 fluorescence has an 
elongated shape. As cell grows, nuclei tend to clump together and to look like one large cluster. In these 
cases, the detection is confounded and often makes many false positives, i.e., identifying background 
areas as nuclei.  
2.1 Nucleus Detection 
To detect nuclei, we first obtain the initial segmentation of the objects by Otsu method (Otsu 
1979) which is a global thresholding technique. Since global thresholding may not be optimal, the true 
nuclei may be (partially) missed. To compensate for the possible lose, an iterative region growing 
method is used; the initial threshold value is th0=AVG(O)±STD*(O), and at iteration i, the threshold value 
is updated as thi = AVG(O) ±(1-0.1*i)*STD(O) where O is the pixels of the identified area and AVG and 
STD are the average and standard deviation of the area, respectively. For each identified candidate 
areas, we group similar pixels together by applying multi-threshold segmentation method based on 
MHFFCM (Wang et al. 2006). In principle, given n data points   *  +   
 , it generates an optimal 
partition by minimizing the following objective function:  
   ∑∑[  (  )]
 
‖     ‖
 
 
   
 
   
 
where c, b,   (  ), and    denotes the number of groups, the exponential weight factor, the 
membership degree of    to jth group, and the center of jth group, respectively. For an image, data 
points are generated at each intensity level and contain intensity and spatial information. For instance, 
at intensity level i,    *                       + is defined where    and    denote the average 
horizontal and vertical coordinates, respectively.    and    are designated as standard deviation of the 
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location of all pixels with the intensity level i and frequency of the intensity level i, respectively.    and 
    represent average and standard deviation of the distances from the center of all pixels with the 
intensity level i, respectively. Then, individual nucleus is identified. Ordering clusters in ascending order 
of the average intensity   *          +, the roundness of the cluster(s) is computed as adding new 
cluster at a time according to the order and identify the union of clusters (g*) resulting in the best 
roundness score.  
         
  ⋃ 
         ( ) 
         ( )  
           ( )             ( )
 
 
where Qhull_ratio and Bound_ratio denote a ratio between the area of a cluster and the areas of convex 
hull and minimum bounding circle of the cluster, respectively. We require the size of the nucleus to be 
>0.5 * Nmedian where Nmedian is the median size of all candidate objects. 
2.2 Green Fluorescence Detection 
We segment green fluorescence of MCF-7 by applying the same method with nuclei, but 
different rules are invoked to remove artifacts:                 ,               and size > 10 
pixels.              is a ratio of major and minor axes. Then, the detected segments are removed from 
the original image, and Otsu’s method and iterative region-growing method are applied to find 
candidate areas of green fluorescence of MRC-5. For the candidate areas, the size and shape are 
examined: size > 10 pixels and                 .  
2.3 Count Activated Cells 
Since a series of images are taken, it is likely that the same cells appear in the adjacent images. If 
such cells exist, we only use the nucleus which has the largest intensity in the original image. Using the 
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segmented nucleus and green fluorescence, we identify the activated cells: if >30% of the pixels of 
nucleus are the areas of the green fluorescence, the nucleus is designated as the nucleus of an activated 
cell. 
3.  Calibration of Automated Cell and Area quantification  
Tumor cells were identified and distinguished from fibroblasts by Immunofluorescence labeling 
for nuclei and cell body. The immunofluorescently stained gels were then analyzed by image analysis. 
Carcinoma cell clusters composed of one cell to more than a hundred cells were included in the analysis.  
3.1 Cell number for automated counting calibration 
To determine whether the nuclei and cell body area is an acceptable surrogate measure of cell 
number, carcinoma nuclei were counted manually in selected clusters and the compared with software 
counting.  The results can be seen in figure 28, which indicates at low cell number there is agreement 
between the techniques, however at larger number of cells the software systemically under counts as 
compared to the hand counting.   
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Figure 28 MCF-7 cell counting under control conditions.  Selected immunofluorescence images were chosen to which ranged 
from 1 to 200.  The results are plotted for software counting and hand counting.  The software systemically under counted in 
larger number of cells 
3.2 Calibration of Area and cell number 
An initial quantitative assessment of cell growth was performed by measuring the total area 
occupied by carcinoma cell clusters. 
 
Figure 29 Relationship between MCF-7 cell cluster area and cell number. 
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A standard curve was generated by assessing the area of a size MCF-7 cell and extrapolating the area 
that multiple cells would occupy for up to 150 cells, which was fit to a linear line.  Then the software 
computation of the area for cells ranging up to 150 was plotted and fit to a 2nd polynomial (Figure 29).  
Using the two fitted equations we find that the difference at lower range of cells is small.  However, at 
large cell numbers the bias between the standard and software calculated curves gets larger.   
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APPENDIX B 
DESIGNING A TREATMENT PLAN 
 
The goal of radiotherapy treatment planning is to justify an effective treatment that will deliver 
a precise irradiation dose to the target volume without causing damage to the surrounding normal 
tissues. Therefore patient positioning, target volume definition and irradiation field placement are very 
critical steps while planning the irradiation process. 
1. Collect patient’s CT data including attached aluminum markers. 
2. CT data set is transferred to a Virtual Simulator. The physician defines the tumor volume and the 
organs at risk and she/he will place the necessary fields relative to the tumor volume. 
3. The simulation plan and the CT data are transferred via DICOM (Digital image and Communication in 
Medicine) server to the Treatment Planning System (TPS) for dose calculation and final treatment plan 
optimization. 
4. Verify patient position on LINAC before irradiation. 
5. Perform treatment on the treatment machine (Linear Accelerator or LINAC). 
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Figure 30 Current clinical routine for external beam treatment delivery 
 
The breast is prescribed 4500 cGy for five weekly fractions for a total of 25 fractions each with 
180cGy per day.  The use of energy greater than 6 MV photons for these patients would have resulted in 
under dose to the superficial tissue just below the skin surface.  Therefore, two tangential off-parallel 
fields of 6 MV photons, each with wedges, were designed.  Because of the breast shape is irregular and 
the volume of the breast tissue decreases towards the nipples, wedges are used on beams for breast 
cancer patients. Different wedges are used depending on the specific patient breast shape, as shown in 
the figure 34 below. In addition, the off-parallel tilt reduced the amount of beam deviation into the 
lungs. The dose within the target volume is also kept to within 10% dose variance in keeping with 
common standards.   
Below is the procedure for completing a dosimetry plan for breast cancer external beam 
radiation therapy.  Figure 31 shows patient setup. The user can modify basic setup as well as couch 
removal and laser localization.  Figure 32 shows the counters including regions of interest and display 
options.  Figure 33 allows the user to assign points of interest such as the isocenter.  Figure 34 shows the 
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beams.  Figure 35 allows the user to compute dose and assign a dose grid and well as dose computation 
method. 
 
 
Figure 31 Patient positioning and treatment fields for treating the intact breast using a three-field isocentric technique.  The 
3-window layout of the system showing CT slices (from superior to inferior). On the left side the parameter controls 
windows, the top window is the transverse view, the lower left is the sagittal view and the lower right is the coronal view.   
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Figure 32 Contouring of a tumor bed and incision site on 3-D treatment planning.  Colored contours of the lumpectomy 
region shown in red contour.  As pictured are regions of interest such as the lungs (green and blue), spinal cord (purple) and 
heart (yellow).   
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Figure 33 An isocenter (red crosshair) is placed within the gross tumor volume to allow user to assign localization for 
treatment planning and patient positioning during treatment.   
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Figure 34 Two-field technique for treatment of the breast, intermediate step in development of tangent pair. After opposing 
medial field, the new lateral field has a diverging deep edge. Additional gantry rotation will result in the desired coplanar 
deep field edge.   
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Figure 35 Left-sided tumor in lateral breast, showing minimal irradiation of the heart and lung in the tangential fields.   
Shown is the dose distribution for a prescribed at a depth of 5 cm.  Dose distribution of tangential fields created using lung 
inhomogeneity corrections and forward planning, with additional medial and lateral segments added to improved 
homogeneity (not done for this patient). Isodose color key: blue, 100% of prescribed dose. 
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APPENDIX C 
MTT ASSAY 
 
The non-radioactive, colorimetric assay system using MTT was first described by Mossman and 
co-workers (Biedler et al. 1973). It is used for the measurement of cell proliferation in response to 
growth factors, cytokines and nutrients as well as for the measurement of cytotoxocity (Pieters et al. 
1990). MTT, 3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyl tetrazolium bromide, is a yellow tetrazolium salt 
which can be transformed into purple colored formazan crystals by metabolic active cells. This cellular 
reduction involves the pyridine nucleotide cofactors NADH and NADPH (Slater 1963).  The larger the 
number of mitochondria, the more MTT will be transformed into formazan.  The photometric 
measurement of a 96-well plate is performed with a spectrophotometer. Since reduction of MTT can 
only occur in metabolically active cells, the level of activity is a measure of the viability of the cells.  MTT 
provides sensitive and reproducible indices of growth as well as sensitivity in individual cell lines over 
the course of multiple passages. 
The method described in Protocol can be performed using standard laboratory equipment and 
individual reagents. MTT assay where purchased from Sigma (St. Louis, MO) and were used according to 
the manufacturer’s instructions. The method is described for cells in a 96-well plate. Prior to performing 
experiments, a standard curve for a given cell type by MTT assay of known numbers of cells over a range 
of approximately 5000–120000 was done.  
Advantages of the MTT assay are that responses of cell lines which do not grow as colonies can 
be measured, and moreover it is less time consuming and less prone to personal interpretations because 
of the automated read-out. With calibration curves it is possible  
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1) To overcome the absence of a linear relationship between cell number and the higher absorbance 
values, 2) To extend the range of values, and 3) To correct for the differences in formazan production 
between cell lines.  
PROTOCOL: 
THE MTT ASSAY 
EQUIPMENT, MATERIALS AND REAGENTS 
Spectrophotometer: Emax reader (Molecular Devices, Wokingham, UK) with software Softmax PRO.  
MTT stock solution 5 mg ml−1: dissolve 50 mg MTT in a total volume of 10ml phosphate-buffered saline.  
Solution was stored at −20°C. Working concentration MTT solution: 0.5 mg ml−1 MTT in PBS.  
Dimethylsulfoxide (DMSO) were purchased from ATCC (Rockville, MD, USA). 
METHOD 
1. Incubate cells seeded in the wells of a 96-well plate with test growth factors for the desired time 
periods. Aspirate medium and add 30 μl per well of 0.5 mg ml−1 MTT solution. Incubate for 4 hours at 
37°C in the tissue culture incubator. 
2. Remove medium and add 100 μl per well of DMSO. Measure absorbance at 570 nm with a reference 
wavelength in the spectrophotometric plate reader. Calculate cell numbers from absorbance using the 
standard curve. 
Calculation of Absorbance rate: 
Once a linear range was found from the standard curves, we chose the 20000 cell concentration 
to observe for a 5 day period since in fell within linear range of 10000 to 30000 cells.   The absorbance 
values at day 0, 3 and 5 were plotted and the slope taken to derive a rate of absorbance changes over 
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the period of time (Figure 36).  What is plot in the figure is the number of cells that where plated initially 
at day 0 and allowed to grow over day 3 and 5 and then measured.   
 
Figure 36 The MTT assay done on the well plate containing an initial value of 20,000 cells observed over a 5 day period for 
control and irradiation sample. 
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